WO2001023347A1 - Novel aromatic compounds - Google Patents

Novel aromatic compounds Download PDF

Info

Publication number
WO2001023347A1
WO2001023347A1 PCT/DK2000/000530 DK0000530W WO0123347A1 WO 2001023347 A1 WO2001023347 A1 WO 2001023347A1 DK 0000530 W DK0000530 W DK 0000530W WO 0123347 A1 WO0123347 A1 WO 0123347A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenoxy
phthalic acid
nitrobenzoylamino
dimethyl ester
acid
Prior art date
Application number
PCT/DK2000/000530
Other languages
French (fr)
Inventor
Marit Kristiansen
Palle Jakobsen
Jane Marie Lundbeck
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP2001526502A priority Critical patent/JP2003510304A/en
Priority to AU74047/00A priority patent/AU7404700A/en
Priority to EP00962253A priority patent/EP1220832A1/en
Publication of WO2001023347A1 publication Critical patent/WO2001023347A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)

Definitions

  • the present invention relates to novel compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes) including overnight or meal treatment and treatment or prevention of long-term complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy; treatment of hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis or ischemia or treatment or prophylaxis of obesity or appetite regulation, pharmaceutical compositions containing these compounds and methods of preparing the compounds.
  • NIDDM non-insulin dependent diabetes
  • Type 1 diabetes or insulin demanding diabetes mellitus (IDDM), which arises when patients lack ⁇ -cells producing insulin in their pancreatic glands
  • IDDM insulin demanding diabetes mellitus
  • Type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM)
  • Type 1 diabetic patients are currently treated with insulin
  • Type 2 diabetic patients are treated either with sulphonylureas that stimulate ⁇ -cell function or with agents that enhance the tissue sensitivity of the patients towards insulin or with insulin.
  • the liver produces glucose in order to avoid hypoglycaemia.
  • This glucose production is derived either from the release of glucose from glycogen stores or from gluconeogenesis, which is a de novo intracellular synthesis of glucose.
  • the regulation of hepatic glucose output is poorly controlled and is increased, and may be doubled after an overnight fast.
  • there exists a strong correlation between the increased fasting plasma glucose levels and the rate of hepatic glucose production (reviewed in R.A. De Fronzo: Diabetes 37, 667 - 687 (1988); A. Consoli: Diabetes Care 15, 430 - 441 (1992); and J.E. Gerich: Horm.Metab.Res. 26, 18 - 21 (1992)).
  • hepatic glucose production will be increased in Type 1 diabetes, if the disease is not properly controlled by insulin treatment.
  • Substituted N-(indole-2-carbonyl)-glycinamides acting as glycogen phosphorylase inhibitors are disclosed in WO96/39384, WO96/39385 and in EP-A-0 846 464.
  • Piperidine and pyrrolidine compounds acting as glycogen phosphorylase inhibitors are disclosed in WO95/24391 , WO 97/09040, WO 98/40353, and WO 98/50359.
  • Atherosclerosis a disease of the arteries, is recognized to be the leading cause of death in the United States and Western Europe. The pathological sequence leading to atherosclerosis and occlusive heart disease is well known.
  • fatty streaks in the carotid, coronary and cerebral arteries and in the aorta. These lesions are yellow in colour due to the presence of lipid deposits found principally within smooth-muscle cells and in macrophages of the intima layer of the arteries and aorta. Further, it is postulated that most of the cholesterol found within the fatty streaks, in turn, give rise to development of the "fibrous plaque", which consists of accumulated intimal smooth muscle cells laden with lipid and surrounded by extra-cellular lipid, collagen, elastin and proteoglycans. The cells plus matrix form a fibrous cap that covers a deeper deposit of cell debris and more extracellular lipid.
  • the lipid is primarily free and esterified cholesterol.
  • the fibrous plaque forms slowly, and is likely in time to become calcified and necrotic, advancing to the "complicated lesion" which accounts for the arterial occlusion and tendency toward mural thrombosis and arterial muscle spasm that characterize advanced atherosclerosis.
  • Epidemiological evidence has firmly established hyperlipidemia as a primary risk factor in causing cardiovascular disease (CVD) due to atherosclerosis.
  • CVD cardiovascular disease
  • leaders of the medical profession have placed renewed emphasis on lowering plasma cholesterol levels, and low density lipoprotein cholesterol in particular, as an essential step in prevention of CVD.
  • the upper limits of "normal” are now known to be significantly lower than heretofore appreciated.
  • Independent risk factors include glucose intolerance, left ventricular hypertrophy, hypertension, and being of the male sex.
  • Cardiovascular disease is especially prevalent among diabetic subjects, at least in part because of the existence of multiple independent risk factors in this population. Successful treatment of hyperlipidemia in the general population, and in diabetic subjects in particular, is therefore of exceptional medical importance.
  • Hypertension is a condition, which occurs in the human population as a secondary symptom to various other disorders such as renal artery stenosis, pheochromocytoma, or endocrine disorders.
  • hypertension is also evidenced in many patients in whom the causative agent or disorder is unknown. While such "essential" hypertension is often associated with disorders such as obesity, diabetes, and hypertriglyceridemia, the relationship between these disorders has not been elucidated. Additionally, many patients display the symptoms of high blood pressure in the complete absence of any other signs of disease or disorder.
  • hypertension can directly lead to heart failure, renal failure, and stroke (brain haemorrhaging). These conditions are capable of causing short-term death in a patient. Hypertension can also contribute to the development of atherosclerosis and coronary disease. These conditions gradually weaken a patient and can lead to long-term death.
  • the exact cause of essential hypertension is unknown, though a number of factors are believed to contribute to the onset of the disease. Among such factors are stress, uncontrolled emotions, unregulated hormone release (the renin, angiotensin aldosterone system), excessive salt and water due to kidney malfunction, wall thickening and hypertrophy of the vasculature resulting in constricted blood vessels and genetic factors.
  • stress uncontrolled emotions
  • unregulated hormone release the renin, angiotensin aldosterone system
  • excessive salt and water due to kidney malfunction
  • wall thickening and hypertrophy of the vasculature resulting in constricted blood vessels and genetic factors.
  • Insulin a peptide hormone whose primary actions are to promote glucose utilization, protein synthesis and the formation and storage of neutral lipids, also acts to promote vascular cell growth and increase renal sodium retention, among other things. These latter functions can be accomplished without affecting glucose levels and are known causes of hypertension. Peripheral vasculature growth, for example, can cause constriction of peripheral capillaries, while sodium retention increases blood volume. Thus, the lowering of insulin levels in hyperinsulinemics can prevent abnormal vascular growth and renal sodium retention caused by high insulin levels and thereby alleviates hypertension. Cardiac hypertrophy is a significant risk factor in the development of sudden death, myocardial infarction, and congestive heart failure.
  • cardiac events are due, at least in part, to increased susceptibility to myocardial injury after ischemia and reperfusion, which can occur in out-patient as well as perioperative settings.
  • Both non-cardiac and cardiac surgery are associated with substantial risks for myocardial infarction or death.
  • Some 7 million patients undergoing non-cardiac surgery are considered to be at risk, with incidences of perioperative death and serious cardiac complications as high as 20-25% in some series.
  • perioperative myocardial infarction is estimated to occur in 5% and death in 1-2%.
  • Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension, and diabetes.
  • the incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world.
  • Except for exercise, diet and food restriction no convincing pharmacological treatment for reducing body weight effectively and acceptably currently exist.
  • due to its indirect but important effect as a risk factor in mortal and common diseases it will be important to find treatment for obesity and/or means of appetite regulation.
  • the term obesity implies an excess of adipose tissue.
  • obesity is best viewed as any degree of excess adiposity that imparts a health risk.
  • the cut off between normal and obese individuals can only be approximated, but the health risk imparted by the obesity is probably a continuum with increasing adiposity.
  • the Framingham study demonstrated that a 20% excess over desirable weight clearly imparted a health risk (Mann GV N.Engl.J.Med 291 :226, 1974).
  • BMI body mass index
  • the regulation of eating behaviour is incompletely understood. To some extent appetite is controlled by discrete areas in the hypothalamus: a feeding centre in the ventrolateral nucleus of the hypothalamus (VLH) and a satiety centre in the ventromedial hypothalamus (VMH).
  • the cerebral cortex receives positive signals from the feeding centre that stimulate eating, and the satiety centre modulates this process by sending inhibitory impulses to the feeding centre.
  • the satiety centre may be activated by the increases in plasma glucose and/or insulin that follow a meal. Meal-induced gastric distension is another possible inhibitory factor. Additionally the hypothalamic centres are sensitive to catecholamines, and beta-adrenergic stimulation inhibits eating behaviour.
  • the cerebral cortex controls eating behaviour, and impulses from the feeding centre to the cerebral cortex are only one input. Psychological, social, and genetic factors also influence food intake.
  • initial weight loss is not an optimal therapeutic goal. Rather, the problem is that most obese patients eventually regain their weight.
  • An effective means to establish and/or sustain weight loss is the major challenge in the treatment of obesity today.
  • One object of the present invention is to provide compounds, which can be used as medicaments for treatment of one or more of the above-mentioned diseases and disorders.
  • a further object of this invention is to provide compounds, which can effectively be used in the treatment of diabetes, preferably Type 2 diabetes, including overnight or meal treatment and preferably for treatment of increased plasma glucose levels.
  • a still further object of this invention is to provide compounds, which can effectively be used as inhibitors of glucose production from the liver.
  • a still further object of this invention is to provide compounds, which can be effectively used as glycogen phosphorylase inhibitors.
  • the compounds of this invention can be used in the treatment of diabetes.
  • the compounds of this invention are active as inhibitors of glucose production from the liver. Consequently, the compounds of this invention can be used for the treatment of the increased plasma glucose levels in diabetics.
  • the present invention relates to novel compounds of the general formula I
  • A is -O-, -S-, >SO, >S0 2 , >CO, >CR9R10, or >NR11 ;
  • R1 and R2 independently are one of the following groups: hydrogen, CN, -C(0)NR6R7, -COOH, -PO(OH) 2 , -SO 2 OH, tetrazole, 1-hydroxy-1 ,2-diazole, 1-hydroxytriazole, 1- hydroxyimidazole, 2-hydroxytriazole, or 1-hydroxytetrazole; when R1 or R2 is hydrogen, the other of R1 and R2 is -PO(OH) 2 or -SO 2 OH; or R1 and R2 together may form an anhydride or an imide; R3 and R4 independently are Ci-s-alkyl, C 2-8 -alkenyl, C 2-8 -alkynyl, or C 3-8 -cycloalkyl, each optionally substituted with halogen, hydroxy, -SH, -SOR6, -SO 2 R6, -NR6R7, -NHCOR7, C 1-8 -alkoxy, N0 2 , trifluorome
  • R5 is -CO-R8, -CH 2 -R8, or -CS-R8; wherein R8 is aryl, C 1-8 -alkyl, C 2-8 -alkene, phenyl- C 1-8 -alkyl, hetereoaryl, or C 3-8 -cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO 2 R6, NO 2 , -NR6R7,
  • R6 and R7 independently are hydrogen, C 1-8 -alkyl, aryl, phenyl-C 1-8 -alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH 2 , NO 2 , -NH(C 1-8 -alkyl), -N(C 1-8 -alkyl) 2 , -NHCO(C 1-8 -alkyl), C 1-8 -alkoxy, and trifluoromethoxy;
  • R9 and R10 independently are hydrogen, hydroxy, SH, halogen, or C 1-8 -alkyl
  • R11 is hydrogen, C 1-8 -alkyl, -carbonyl(C ⁇ . 8 -alkyl), or phenyl-C 1-8 -alkyl.
  • A is -O- or -S-, preferably A is -O-.
  • R1 and R2 both are -COOH or CN, preferably -COOH or R1 and R2 together form an imide.
  • R3 is hydrogen
  • R4 is hydrogen
  • R5 is -CO-R8, wherein R8 is aryl, C 1-8 - alkyl, C 2-8 -alkene, phenyl-C 1-8 -alkyl, hetereoaryl, or C 3-8 -cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S0 2 R6, NO 2 , -NR6R7, -NHCOR7, C 1-8 -alkyl, C 1-8 -alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C 1-8 -alkylthio, -COOR6, -SO 2 OH, -PO(OH) 2 , -CN, -NHCOR7, -CONHSO 2 R7, -SO 2 NHR7, C 1-8 -
  • R5 is -CO-R8, wherein R8 is aryl or hetereoaryl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S0 2 R6, N0 2 , -NR6R7, -NHCOR7, C 1-8 -alkyl, C 1-8 -alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C 1-8 - alkylthio, -COOR6, -S0 2 OH, -PO(OH) 2 , CN, -NHCOR7, -CONHSO 2 R7, -S0 2 NHR7, C 1-8 - alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, C 1-8 -alkyl, aryl,
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO 2 R6, NO 2 , -NR6R7, -NHCOR7, C 1-8 -alkyl, C 1-8 -alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C ⁇ - alkylthio, -COOR6, -SO 2 OH, -PO(OH) 2 , CN, -NHCOR7, -CONHSO 2 R7, -SO 2 NHR7, C 1-8 - alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, C 1-8 -alkyi, aryl, phenyl-C 1-8 -
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, COOR6, NO 2 , -SO 2 CH 3 , CN, C 1-8 -alkyl (preferably methyl, tert-butyl, isopropyl, pentyl, heptyl), perhalomethyl (preferably trifluoromethyl), C 1-8 -alkoxy (preferably methoxy or ethoxy), perhalomethoxy (preferably trifluoromethoxy), C 1-8 -alkylthio (preferably methylthio), -CO-R6, -NR6R7, -NH-CO-R7, and -OR6; wherein R6 and R7 independently are hydrogen, C ⁇ _s-alkyl, aryl, phenyl-C 1-8 -alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is NO 2 .
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is halogen (preferably bromo or chloro).
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -CO-R6, wherein R6 is C 1-8 -alkyl (preferably CH 3 ) or substituted aryl (preferably phenyl) substituted with halogen or substituted with Ci-s-alkyl (preferably CH 3 ).
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -NH-CO-R7, wherein R7 is C 1-8 -alkyl (preferably CH 3 ).
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -NR6R7, wherein R6 and R7 independently are hydrogen or C 1-8 -alkyl (preferably CH 3 ).
  • R5 is -CO-R8, wherein R8 is phenyl substituted with one or more substituents and at least one of the substituents is -OR6, wherein R6 is C 1-8 -alkyl (preferably methyl).
  • R5 is -CO-R8, wherein R8 is benzo[1 ,3]dioxole, 2,3-dihydrobenzofuran, or benzofuran, each optionally substituted with one or more substituents selected from halogen, C 1-8 -alkyl (preferably methyl), and C 1-8 - alkoxy (preferably methoxy).
  • the present invention relates also to novel compounds of the general formula la
  • R1 and R2 independently are one of the following groups: hydrogen, CN, -C(O)NR6R7,
  • R1 or R2 when R1 or R2 is hydrogen, the other of R1 and R2 is -PO(OH) 2 or -SO 2 OH; or R1 and R2 together may form an anhydride or an imide;
  • R5 is -CO-R8, -CH 2 -R8, or -CS-R8; wherein R8 is aryl, C 1-8 -alkyl, C 2-8 -alkene, phenyl-
  • R1 and R2 are -COOH.
  • R5 is -CO-R8, wherein R8 is aryl, C 1-8 -alkyl, C 2-8 -alkene, phenyl-C ⁇ -alkyl, hetereoaryl, or C 3 .
  • the present invention also relates to novel compounds of the general formula lb
  • R5 is -CO-R8, wherein R8 is aryl, C 1-8 -alkyl, C 2 -s-alkene, phenyl-C 1-8 -alkyl, hetereoaryl, or C 3-8 -cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO 2 R6, NO 2 , -NR6R7, -NHCOR7, C 1-8 -alkyl, C 1-8 -alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C 1-8 -alkylthio, -COOR6, -SO 2 OH, -PO(OH) 2 , -CN, -NHCOR7, -CONHS0 2 R7, -SO 2 NHR7, and tetrazole; wherein
  • R6 and R7 independently are hydrogen, C 1-8 -alkyl, aryl, phenyl-C ⁇ -alkyl, or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH 2 , -SH, -SOR6, -SO 2 R6, NO 2 , -NH(C 1-8 -alkyl), -N(C 1-8 -alkyl) 2 , -NHCO(C 1-8 -alkyl), C ⁇ -alkoxy, and trifluoromethoxy.
  • R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, COOR6, N0 2 , -SO 2 CH 3 , CN, C 1-8 -alkyl (preferably methyl, tertbutyl, isopropyl pentyl, heptyl), perhalomethyl (preferably trifluoromethyl), C 1-8 -alkoxy (preferably methoxy or ethoxy), perhalomethoxy (preferably trifluoromethoxy), C 1-8 -alkylthio (preferably methylthio), -CO-R6, -NR6R7, -NH-CO-R7, and -OR6; wherein R6 and R7 independently are hydrogen, C 1-8 -alkyl, aryl, phenyl-C 1-8 -alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH 2
  • the compounds of the present invention may have one or more asymmetric centres and it is intended that stereoisomers (optical isomers), as separated, pure or partially purified stereoisomers or racemic mixtures thereof are included in the scope of the present invention.
  • the compounds of formula I, la or lb may optionally be prepared in the form of pharmaceutically acceptable basic salts or mixtures thereof, as pharmaceutically acceptable metal salts or - optionally alkylated - ammonium salts.
  • salts include inorganic and organic basic addition salts and the like, and include bases related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science 66, 2 (1977) and incorporated herein by reference, or lithium, sodium, potassium, magnesium and the like.
  • the compounds of formula I, la or lb may be administered in pharmaceutically acceptable basic addition salt form or, where appropriate, as a alkali metal or alkaline earth metal or lower alkylammonium salt. Such salt forms are believed to exhibit approximately the same order of activity as the free acid forms.
  • addition salts are the hydrates, which the present compounds are able to form.
  • the basic addition salts may be obtained as the direct products of compound synthesis.
  • the free acid may be dissolved in a suitable solvent containing the appropriate base, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan. Such solvates are also contemplated as being within the scope of the present invention.
  • the present invention relates to a compound of the above general formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof or any optical isomer thereof or a mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof for use as a medicament.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, a compound of the above general formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof or any optical isomer thereof mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof together with a pharmaceutically acceptable carrier or diluent.
  • the present invention relates to a method for the treatment of diabetes, preferably Type 2 diabetes the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention.
  • the present invention relates to a method for the treatment of glycogen phosphorylase dependent diseases the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention.
  • the present invention relates to a method for inhibition of glucose production from the liver, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention.
  • the present invention relates to a method for the treatment or prophylaxis of obesity or appetite regulation, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention.
  • the present invention relates to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament.
  • the present invention relates to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for the treatment or prevention of diabetes, preferably Type 2 diabetes.
  • the present invention relates to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for inhibiting the glucose production from the liver.
  • the present invention relates furthermore to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for inhibiting liver glycogen phosphorylase.
  • the present invention relates furthermore to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for the treatment or prophylactic of obesity or appetite regulation.
  • the present invention relates furthermore to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of hyperglycemia, hypercholesterolemia, hyperinsulinemia, atherosclerosis, hyperlipidemia or hypertension.
  • treatment is intended to include prophylactic treatment.
  • halogen means fluorine, chlorine, bromine or iodine.
  • perhalomethyl means trifluoromethyl, trichloromethyl, tribromomethyl, or triiodomethyl.
  • C 1-8 -alkyl refers to a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2- methylbutyl, 3-methylbutyl, 4-methylpentyl, neopentyl, n-pentyl, n-hexyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1 ,2,2-trimethylpropyl and the like.
  • C 1-8 -alkyl as used herein also includes secondary C 3-8 -alkyl and tertiary C 4-8 -alkyl.
  • C 2-8 -alkenyl as used herein alone or in combination represents a straight or branched hydrocarbon group containing from 2 to the specified number of carbon atoms and at least one double bond.
  • Typical C 2-8 -alkenyl groups include, but are not limited to, vinyl, 1- propenyl, 2-propenyl, iso-propenyl, 1 ,3-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl- 1 -propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2- hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl and the like.
  • C M -alkynyl represents a straight or branched hydrocarbon group containing from 2 to the specified number of carbon atoms and at least one triple bond.
  • Examples of “C 2-8 -alkynyl” groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3- pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 5-hexynyl, 2,4-hexadiynyl and the like.
  • C 3 . 8 -cycloalkyl represents a carbocyclic group having from 3 to 8 carbon atoms.
  • Typical d-s-cycloalkyl groups include, but are not limited to, cyciopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
  • d ⁇ -alkoxy refers to the radical -0-d.s-alkyi where C 1-8 -alkyl is as defined above.
  • Typical C ⁇ -alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, sec-butoxy, terf-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.
  • C 1-8 -alkylthio refers to a straight or branched monovalent substituent comprising a lower alkyl group linked through a divalent sulphur atom having its free valence bond from the sulphur atom and having 1 to 8 carbon atom such as e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio and the like.
  • C ⁇ . 8 -alkoxycarbonyl refers to a monovalent substituent comprising a d_s-alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tertbutoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.
  • phenyl-C 1-8 -alkyl refers to a straight or branched saturated carbon chain containing from 1 to 8 carbon substituted with phenyl; such as e.g. benzyl, phenylethyl, 3-phenylpropyl and the like.
  • C 1-8 -alkylphenyl refers to phenyl substituted by C 1-8 -alkyl as defined above.
  • carbamoyl refers to NH 2 C(O)-.
  • carbonyl(d. 8 )-alkyl refers to carbonyl substituted by (C 1-8 )- alkyl as defined above.
  • aryl as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems.
  • heteroaryl as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; such as e.g. furyl, thienyl, pyrrolyl and the like. Heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below.
  • aryl and “heteroaryl” includes, but are not limited to phenyl, biphenyl, indene, fluorene, naphthyl (1-naphthyl, 2-naphthyl), anthracene (1-anthracenyl, 2- anthracenyl, 3-anthracenyl), thiophene (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, oxatriazolyl, thiathazolyl, quinazolin, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyrazolyl (1-pyrazolyl, 3-pyrazo
  • the present invention also relates to partly or fully saturated analogues of the ring systems mentioned above.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
  • a pharmaceutical composition of the present invention may comprise a compound of formula (I, la or lb) combined with one or more compounds.
  • compositions containing a compound according to the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19 th Ed., 1995.
  • the compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
  • compositions include a compound of formula (I, la or lb) or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material, which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
  • the formulations of the present invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
  • the route of administration may be any route, which effectively transports the active compound of formula (I, la or lb) to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • the preparation may contain a compound of formula I, la or lb dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • Active compound 250 mg
  • the compounds of the present invention may be administered to a mammal, especially a human, in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g. hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlioidemla or obesity, and especially diabetes.
  • Such mammals also include animals, both domestic animals, e.g. household pets, and non- domestic animals such as wildlife.
  • the compounds of the present invention are effective over a wide dosage range.
  • dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used.
  • a most preferable dosage is about 0.5 mg to about 250 mg per day.
  • the exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in harge.
  • the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds of formula I, la or lb admixed with a pharmaceutically acceptable carrier or diluent.
  • the present invention also encompasses prodrugs of a compound according to the invention which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances.
  • prodrugs will be functional derivatives of a compound according to the present invention which are readily convertible in vivo into a compound according to the present invention.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the ester derivatives of formula I, la or lb could be suitable prodrugs.
  • the present invention also encompasses active metabolites of a compound according to the invention.
  • a compound according to the invention may be administered in combination with further pharmacologically active substances e.g. other antiobesity agents or appetite regulating agents.
  • Such agents may be selected from the group consisting of CART agonists, NPY antagonists, MC4 agonists, orexin antagonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, ⁇ 3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK agonists, serotonin re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, GLP-1 , leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR ⁇ agonists.
  • the antiobesity agent is leptin.
  • the antiobesity agent is dexamphetamine or amphetamine.
  • the antiobesity agent is dexfenfluramine. In still another preferred embodiment the antiobesity agent is sibutramine.
  • the antiobesity agent is orlistat. In another preferred embodiment the antiobesity agent is mazindol or phentermine.
  • a compound according to the invention may be administered in combination with further pharmacologically active substances e.g. other lipid lowering agents.
  • a compound according to the present invention may also be administered in combination with an antidiabetic or other pharmacologically active material, including compounds for the treatment and/or prophylaxis of insulin resistance and diseases, wherein insulin resistance is the pathophysiological mechanism.
  • Suitable antidiabetics comprise insulin, GLP-1 derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference, as well as orally active hypoglycaemic agents.
  • the orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, oxadiazolidinediones, thiazolidinediones, ⁇ -glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S, which are incorporated herein by reference, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the lipid metabolism, compounds lowering food intake, PPAR and RXR agonists and agents acting on the ATP-dependent potassium channel of the ⁇ -cells.
  • a compound according to the invention is administered in combination with insulin.
  • a compound according to the present invention is administered in combination with a sulphonylurea such as e.g.tolbutamide, glibenclamide, glipizide or glicazide.
  • a compound according to the present invention is administered in combination with a biguanidine such as e.g. metformin.
  • a compound according to the present invention is administered in combination with a thiazolidinedione such as e.g. troglitazone, ciglitazone, pioglitazone, rosiglitazone and the compounds disclosed in WO 97/41097 to Dr. Reddy's Research Foundation, especially 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2- quinazolinylmethoxy]phenyl]-methyl]-2,4-thiazolidinedione.
  • an ⁇ -glucosidase inhibitor such as e.g. voglibose or acarbose.
  • a compound according to the present invention is administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ -cells such as e.g. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ -cells such as e.g. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide.
  • a compound according to the present invention may be administered in combination with an antihypertensive agent.
  • antihypertensive agents examples include ⁇ - blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy,19 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. Any novel feature or combination of features described herein is considered
  • the present invention also relates to methods of preparing the above-mentioned compounds.
  • A is O or S.
  • Lg is a leaving group such as F, Cl, Br, I, NO 2 , -OSO 2 CH 3 or -OTs.
  • R1 , R2, R3 and R4 have the meanings set forth above.
  • R1 , R2, R3, and R4 are labile groups e.g. acids or hydroxy they are protected as well known derivatives such as carboxylic esters, sulphonic esters, phosphoric esters, nitrile, amides, or cyclic anhydrides or cyclic amides or as e.g. ethers.
  • Mb and 11 lb are reacted in a aprotic solvent such as CS 2 with a Friedel Craft catalyst such as AICI 3 , FeCI 3 , SnCI 4 or ZnCI 2 to make IVb as described in J.Org.Chem. 48(13) 2281- 2285 (1983) or Justus Liebigs. Ann. Chem. 220, 250 (1993). Both references are incorporated herein by reference.
  • aprotic solvent such as CS 2
  • a Friedel Craft catalyst such as AICI 3 , FeCI 3 , SnCI 4 or ZnCI 2
  • reaction can be made by cross coupling or Grignard coupling.
  • X is B(OH) 2 , Cl, Br, I, CIMg-, BrMg-, or IMg- as described in Synthetic Commun. V ⁇ _, 513 (1981 ), Tetrahedron 54(12), 2953-2966 (1998), J.Chem.Soc.Chem.Com. 3, 305-306 (1995), J.Amer.Chem.Soc. 18(42), 10220-10227 (1996) or J.Chem.Soc.Perk.Trans. 1(6) 719-730 (1993) all incorporated herein by reference.
  • R1 , R2, R3, R4 and R8 have the meanings set forth above.
  • R1 , R2, R3 and R4 are labile groups e.g. acids or hydroxy, they are protected as well known derivatives such as carboxylic esters, sulphonic esters, phosphoric esters, nitrile, amides, or cyclic anhydrides or cyclic amides or as e.g. ethers.
  • A is O, S, or N and Lg, R1 , R2, R3, and R4 have the meaning set forth above.
  • Compounds of formula VII can be reduced by catalytic hydrogenation, H 2 ,Pd/C, to form compound IV.
  • a compound of formula IX can be synthesised from the R8-CO 2 H and the amine IV by coupling with HOBt, EDAC and TEA in a solvent such as DMF, CH 2 CI 2 or NMP to produce compounds of formula IX.
  • a compound of formula IV can be reacted with a compound of formula X like Y-CH 2 R8, wherein Y is a leaving group such as Cl, Br, I, -OS0 2 CH 3 , or -OTs, to produce a compound of formula XI in a solvent such as acetone, DMF, DMSO, THF, NMP or CH 2 CI 2 with a base such as NaOH, LiOH, K 2 C0 3 , TEA, DMAP, sodium tert-butoxide, or potassium tert-butoxide.
  • a solvent such as acetone, DMF, DMSO, THF, NMP or CH 2 CI 2
  • a base such as NaOH, LiOH, K 2 C0 3 , TEA, DMAP, sodium tert-butoxide, or potassium tert-butoxide.
  • the substrate Su may be any insoluble or partially insoluble material, to which compounds may be covalently attached.
  • Substrates may be selected from the group consisting of any kind of organic or inorganic polymeric or oligomeric compound.
  • the substrate may be selected from the groups consisting of polystyrene, polyethylene glycol (PEG), polyethylene glycol attached to polystyrene, polyacrylamides, polyamides, polysaccharides and silicates.
  • PEG polyethylene glycol
  • polyacrylamides polyamides
  • polyamides polyamides
  • polysaccharides polysaccharides
  • silicates Depending on the type of substrate chosen, different types of solvents or protecting groups may be used.
  • the linker L is a molecule with at least two reactive sites, which permit its covalent attachment to other molecules or to a substrate. Either the bond of the linker to the substrate or the bond of the linker to other molecules attached to it or the linker itself must be cleavable upon selective exposure to an activator such as a selected chemical activator or other specific conditions, e.g. by treatment with a strong acid or by exposure to electromagnetic radiation or by metal catalysis;
  • an activator such as a selected chemical activator or other specific conditions, e.g. by treatment with a strong acid or by exposure to electromagnetic radiation or by metal catalysis;
  • the starting materials employed in the synthesis of the compounds from formula II, III, V, VI and VIII are either known or may be prepared in conventional manner from commercially available materials, e.g according to the methods described in the examples.
  • Other compounds of the general formula I can be prepared by the above strategy.
  • a variety of functional groups can be introduced in the compounds prepared as outlined above by methods well known to those skilled in the art.
  • the resin was washed with DMF (4x10 ml), methylene chloride (4x10 ml), methanol (4x10 ml), and methylene chloride (4x10 ml).
  • the resin was dried in vac ⁇ o.
  • o-Fluoronitrobenzene 0.4 ml, 3.77 mmol
  • 0.5 M potassium bis(trimethylsilyl)amide 1.2 ml, 0.6 mmol
  • 4-(2-Aminophenylsulfenyl)phthalic acid dimethyl ester Sodium hydride, 60% dispersion in mineral oil, (0.18 g, 4.5 mmol) was added to a solution of 2-aminothiophenol (0.59 ml, 4.0 mmol) in dry DMF (5 ml) at -20°C. The mixture was stirred at -20 to -30°C for 10 minutes. A solution of 4-nitrophthalic acid dimethyl ester (0.83 g, 3.5 mmol) in dry DMF (5 ml) was added dropwise.
  • the reaction mixture was stirred at -30°C ⁇ 5°C for 1 hour and then at room temperature for 20 hours, poured into icewater (20 ml) and finally extracted with ethyl acetate (3x25 ml). The combined organic phase was washed with water (25 ml), dried over magnesium sulphate, and evaporated to dryness in vacuo.
  • the crude product was purified on silica gel (eluent: methylene chloride) to give 4-(2- aminophenylsulfenyl)phthalic acid dimethyl ester (yield: 0.56 g (51 %)) as a golden oil.
  • Ammonium chloride (0.46 g, 8.5 mmol) and sodium azide (0.55 g, 8.5 mmol) were added to a solution of 4-(2-aminophenoxy)phthalonitrile (0.5 g, 2.1 mmol) in DMF (20 ml).
  • Benzaldehyde (1.64 ml, 16.2 mmol) and sodium cyanoborohydride (1.02 g, 16.2 mmol) were added to a solution of 4-aminophthalic acid dimethyl ester (1.7 g, 8.1 mmol) in dry methanol (50 ml) and pH was adjusted to 5.5 - 6 with 2 M hydrogen chloride in methanol (approx. 1 ml).
  • the reaction mixture was stirred at room temperature for 20 hours and evaporated to dryness in vacuo.
  • the residue was partitioned between methylene chloride (50 ml) and water (30 ml). pH was adjusted to 8 and the organic phase was isolated, dried over magnesium sulphate and evaporated to dryness in vacuo.
  • 4-r2-(3-Trifluoromethoxybenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 107) from 4-(2-aminophenoxy)phthalic acid dimethylester (200 mg) and 3-trifluoromethoxybenzoyl chloride (137 mg).
  • 4-r2-(3-Fluorobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 108) from 4-(2-aminophenoxy)phthalic acid dimethylester (200 mg) and 3-fluorobenzoyl chloride (126 mg) (yield: 239 mg (85%).
  • N-Bromosuccinimide (4.3 g, 24.2 mmol) and benzoylperoxide (50 mg) was added to a solution of 4-methylphthalic acid dimethyl ester in carbon tetrachloride (50 ml). The mixture was heated to reflux temperature for two hours, cooled to room temperature and evaporated to dryness in vacuo to give 4-bromomethylphthalic acid dimethyl ester. The crude product was used in the next step without purification.
  • phthalic acid (Compound 125) from 4-[2-(3-nitrobenzoylamino)phenylsulphenyl]phthalic acid dimethylester. Mp: 172.8-173.9°C.
  • 4-r2-(3-Nitrobenzoylamino)benzenesulfinyllphthalic acid (Compound 126) from 4-[2-(3-nitrobenzoylamino)benzenesulfinyl]phthalic acid dimethylester.
  • N- ⁇ 2-[3,4-Bis-(1-benzyl-1 H-tetrazol-5-yl)phenoxy]phenyl ⁇ acetamide (40 mg, 0.07 mmol) was dissolved in ethanol (10 ml). 4N hydrochloric acid (10 ml) was added and the reaction mixture was refluxed for 15 hours. The mixture was evaporated in vacuo and redissolved in methylene chloride and 0.5 N aqueous sodium hydroxide (1 :1) (20 ml).
  • Rat hepatocytes were isolated using a standard two step collagenase technique, and cultured onto collagen coated culture dishes for 72 hours in medium 199 with the addition of dexamethazone (0.1 mM); penicillin/Streptomycin ((100 u/100 mg)/ml) and insulin (1 nM). During the last 24 hours, the hepatocytes were cultured in the presence of high levels of insulin (5 nM) and glucose (15 mM), which result in the incorporation of glucose into glycogen. Therefore, at the time of the experiment, the cells mimic livers from fed animals. Experiments were initiated after 48 hours of culture by 2 times wash of cells and addition of a 20 mM HEPES experimental buffer including balanced salts, but without glucose.
  • test compound was added simultaneously with the experimental buffer.
  • glucagon 0.5 nM was added after 10 minutes in order to stimulate glucose production from liver cells.
  • Phosphorylase was either purchased from Sigma or extracted from pig livers according to Stalmans et. al. (Eur.J. Biochem. 49, 415 (1974)), which reference is hereby incorporated by reference. The activity of phosphorylase was determined as described by Bergmeyer (1983; in: Meth. of Enzymatic Analysis 2, 293-295, Weinheim, (ed.) Verlag Chemie), which reference is hereby incorporated by reference.
  • Compounds of the present invention shows their effect in lowering the glucagon mediated increase in plasma glucose.

Abstract

The present invention relates to novel compounds of general formula (I), pharmaceutical formulations comprising these compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes) as well as methods for treating diabetes comprising administration of these compounds.

Description

NOVEL AROMATIC COMPOUNDS
FIELD OF THE INVENTION
The present invention relates to novel compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes) including overnight or meal treatment and treatment or prevention of long-term complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy; treatment of hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis or ischemia or treatment or prophylaxis of obesity or appetite regulation, pharmaceutical compositions containing these compounds and methods of preparing the compounds.
BACKGROUND OF THE INVENTION
Diabetes is characterised by an impaired glucose metabolism manifesting itself among other things by an elevated blood glucose level in the diabetic patients. Underlying defects lead to a classification of diabetes into two major groups: Type 1 diabetes, or insulin demanding diabetes mellitus (IDDM), which arises when patients lack β-cells producing insulin in their pancreatic glands, and Type 2 diabetes, or non-insulin dependent diabetes mellitus (NIDDM), which occurs in patients with an impaired β-cell function besides a range of other abnormalities. Type 1 diabetic patients are currently treated with insulin, while the majority of Type 2 diabetic patients are treated either with sulphonylureas that stimulate β-cell function or with agents that enhance the tissue sensitivity of the patients towards insulin or with insulin. Among the agents applied to enhance tissue sensitivity towards insulin metformin is a representative example. Even though sulphonylureas are widely used in the treatment of NIDDM this therapy is, in most instances, not satisfactory: In a large number of NIDDM patients sulphonylureas do not suffice to normalise blood sugar levels and the patients are, therefore, at high risk for acquiring diabetic complications. Also, many patients gradually lose the ability to respond to treatment with sulphonylureas and are thus gradually forced into insulin treatment. This shift of patients from oral hypoglycaemic agents to insulin therapy is usually ascribed to exhaustion of the β-cells in NIDDM patients.
In normal subjects as well as in diabetic subjects, the liver produces glucose in order to avoid hypoglycaemia. This glucose production is derived either from the release of glucose from glycogen stores or from gluconeogenesis, which is a de novo intracellular synthesis of glucose. In Type 2 diabetes, however, the regulation of hepatic glucose output is poorly controlled and is increased, and may be doubled after an overnight fast. Moreover, in these patients there exists a strong correlation between the increased fasting plasma glucose levels and the rate of hepatic glucose production (reviewed in R.A. De Fronzo: Diabetes 37, 667 - 687 (1988); A. Consoli: Diabetes Care 15, 430 - 441 (1992); and J.E. Gerich: Horm.Metab.Res. 26, 18 - 21 (1992)). Similarly, hepatic glucose production will be increased in Type 1 diabetes, if the disease is not properly controlled by insulin treatment.
Since existing forms of therapy of diabetes does not lead to sufficient glycaemic control and therefore are unsatisfactory, there is a great demand for novel therapeutic approaches. Since the liver in diabetes is known to have an increased glucose production, compounds inhibiting this activity are highly desirable. Recently, patent applications on inhibitors of the liver specific enzyme, glucose-6-phosphatase, which is necessary for the release of glucose from the liver, have been filed, for example DE-A-4,202,183, DE-A-4,202,184, WO98/40385, WO99/40062, and JP-A- 4-58565.
Substituted N-(indole-2-carbonyl)-glycinamides acting as glycogen phosphorylase inhibitors are disclosed in WO96/39384, WO96/39385 and in EP-A-0 846 464. Piperidine and pyrrolidine compounds acting as glycogen phosphorylase inhibitors are disclosed in WO95/24391 , WO 97/09040, WO 98/40353, and WO 98/50359. Atherosclerosis, a disease of the arteries, is recognized to be the leading cause of death in the United States and Western Europe. The pathological sequence leading to atherosclerosis and occlusive heart disease is well known. The earliest stage in this sequence is the formation of "fatty streaks" in the carotid, coronary and cerebral arteries and in the aorta. These lesions are yellow in colour due to the presence of lipid deposits found principally within smooth-muscle cells and in macrophages of the intima layer of the arteries and aorta. Further, it is postulated that most of the cholesterol found within the fatty streaks, in turn, give rise to development of the "fibrous plaque", which consists of accumulated intimal smooth muscle cells laden with lipid and surrounded by extra-cellular lipid, collagen, elastin and proteoglycans. The cells plus matrix form a fibrous cap that covers a deeper deposit of cell debris and more extracellular lipid. The lipid is primarily free and esterified cholesterol. The fibrous plaque forms slowly, and is likely in time to become calcified and necrotic, advancing to the "complicated lesion" which accounts for the arterial occlusion and tendency toward mural thrombosis and arterial muscle spasm that characterize advanced atherosclerosis. Epidemiological evidence has firmly established hyperlipidemia as a primary risk factor in causing cardiovascular disease (CVD) due to atherosclerosis. In recent years, leaders of the medical profession have placed renewed emphasis on lowering plasma cholesterol levels, and low density lipoprotein cholesterol in particular, as an essential step in prevention of CVD. The upper limits of "normal" are now known to be significantly lower than heretofore appreciated. As a result, large segments of Western populations are now realized to be at particular high risk. Independent risk factors include glucose intolerance, left ventricular hypertrophy, hypertension, and being of the male sex. Cardiovascular disease is especially prevalent among diabetic subjects, at least in part because of the existence of multiple independent risk factors in this population. Successful treatment of hyperlipidemia in the general population, and in diabetic subjects in particular, is therefore of exceptional medical importance.
Hypertension (or high blood pressure) is a condition, which occurs in the human population as a secondary symptom to various other disorders such as renal artery stenosis, pheochromocytoma, or endocrine disorders. However, hypertension is also evidenced in many patients in whom the causative agent or disorder is unknown. While such "essential" hypertension is often associated with disorders such as obesity, diabetes, and hypertriglyceridemia, the relationship between these disorders has not been elucidated. Additionally, many patients display the symptoms of high blood pressure in the complete absence of any other signs of disease or disorder.
It is known that hypertension can directly lead to heart failure, renal failure, and stroke (brain haemorrhaging). These conditions are capable of causing short-term death in a patient. Hypertension can also contribute to the development of atherosclerosis and coronary disease. These conditions gradually weaken a patient and can lead to long-term death.
The exact cause of essential hypertension is unknown, though a number of factors are believed to contribute to the onset of the disease. Among such factors are stress, uncontrolled emotions, unregulated hormone release (the renin, angiotensin aldosterone system), excessive salt and water due to kidney malfunction, wall thickening and hypertrophy of the vasculature resulting in constricted blood vessels and genetic factors.
The treatment of essential hypertension has been undertaken bearing the foregoing factors in mind. Thus a broad range of beta-blockers, vasoconstrictors, angiotensin converting enzyme inhibitors and the like have been developed and marketed as antihypertensives. The treatment of hypertension utilizing these compounds has proven beneficial in the prevention of short-interval deaths such as heart failure, renal failure, and brain haemorrhaging. However, the development of atherosclerosis or heart disease due to hypertension over a long period of time remains a problem. This implies that although high blood pressure is being reduced, the underlying cause of essential hypertension is not responding to this treatment. Hypertension has been associated with elevated blood insulin levels, a condition known as hyperinsulinemia. Insulin, a peptide hormone whose primary actions are to promote glucose utilization, protein synthesis and the formation and storage of neutral lipids, also acts to promote vascular cell growth and increase renal sodium retention, among other things. These latter functions can be accomplished without affecting glucose levels and are known causes of hypertension. Peripheral vasculature growth, for example, can cause constriction of peripheral capillaries, while sodium retention increases blood volume. Thus, the lowering of insulin levels in hyperinsulinemics can prevent abnormal vascular growth and renal sodium retention caused by high insulin levels and thereby alleviates hypertension. Cardiac hypertrophy is a significant risk factor in the development of sudden death, myocardial infarction, and congestive heart failure. Theses cardiac events are due, at least in part, to increased susceptibility to myocardial injury after ischemia and reperfusion, which can occur in out-patient as well as perioperative settings. There is an unmet medical need to prevent or minimize adverse myocardial perioperative outcomes, particularly perioperative myocardial infarction. Both non-cardiac and cardiac surgery are associated with substantial risks for myocardial infarction or death. Some 7 million patients undergoing non-cardiac surgery are considered to be at risk, with incidences of perioperative death and serious cardiac complications as high as 20-25% in some series. In addition, of the 400,000 patients undergoing coronary by-pass surgery annually, perioperative myocardial infarction is estimated to occur in 5% and death in 1-2%. There is currently no drug therapy in this area, which reduces damage to cardiac tissue from perioperative myocardial ischemia or enhances cardiac resistance to ischemic episodes. Such a therapy is anticipated to be life- saving and reduce hospitalizations, enhance quality of life and reduce overall health care costs of high risk patients. Another field for the present invention is obesity or appetite regulation.
Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension, and diabetes. The incidence of obese people and thereby also these diseases is increasing throughout the entire industrialised world. Except for exercise, diet and food restriction no convincing pharmacological treatment for reducing body weight effectively and acceptably currently exist. However, due to its indirect but important effect as a risk factor in mortal and common diseases it will be important to find treatment for obesity and/or means of appetite regulation.
The term obesity implies an excess of adipose tissue. In this context obesity is best viewed as any degree of excess adiposity that imparts a health risk. The cut off between normal and obese individuals can only be approximated, but the health risk imparted by the obesity is probably a continuum with increasing adiposity. The Framingham study demonstrated that a 20% excess over desirable weight clearly imparted a health risk (Mann GV N.Engl.J.Med 291 :226, 1974). In the United States a National Institutes of Health consensus panel on obesity agreed that a 20% increase in relative weight or a body mass index (BMI = body weight in kilograms divided by the square of the height in meters) above the 85th percentile for young adults constitutes a health risk. By the use of these criteria 20 to 30 percent of adult men and 30 to 40 percent of adult women in the United States are obese. (NIH, Ann Intern Med 103:147, 1985).
Even mild obesity increases the risk for premature death, diabetes, hypertension, atherosclerosis, gallbladder disease, and certain types of cancer. In the industrialised western world the prevalence of obesity has increased significantly in the past few decades. Because of the high prevalence of obesity and its health consequences, its prevention and treatment should be a high public health priority.
When energy intake exceeds expenditure, the excess calories are stored in adipose tissue, and if this net positive balance is prolonged, obesity results, i.e. there are two components to weight balance, and an abnormality on either side (intake or expenditure) can lead to obesity.
The regulation of eating behaviour is incompletely understood. To some extent appetite is controlled by discrete areas in the hypothalamus: a feeding centre in the ventrolateral nucleus of the hypothalamus (VLH) and a satiety centre in the ventromedial hypothalamus (VMH). The cerebral cortex receives positive signals from the feeding centre that stimulate eating, and the satiety centre modulates this process by sending inhibitory impulses to the feeding centre. Several regulatory processes may influence these hypothalamic centres. The satiety centre may be activated by the increases in plasma glucose and/or insulin that follow a meal. Meal-induced gastric distension is another possible inhibitory factor. Additionally the hypothalamic centres are sensitive to catecholamines, and beta-adrenergic stimulation inhibits eating behaviour. Ultimately, the cerebral cortex controls eating behaviour, and impulses from the feeding centre to the cerebral cortex are only one input. Psychological, social, and genetic factors also influence food intake.
At present a variety of techniques are available to effect initial weight loss. Unfortunately, initial weight loss is not an optimal therapeutic goal. Rather, the problem is that most obese patients eventually regain their weight. An effective means to establish and/or sustain weight loss is the major challenge in the treatment of obesity today.
Thus there remains today a need in the art for compositions and methods that are useful for the treatment or prophylaxis of obesity or appetite regulation. SUMMARY OF THE INVENTION
One object of the present invention is to provide compounds, which can be used as medicaments for treatment of one or more of the above-mentioned diseases and disorders.
A further object of this invention is to provide compounds, which can effectively be used in the treatment of diabetes, preferably Type 2 diabetes, including overnight or meal treatment and preferably for treatment of increased plasma glucose levels.
A still further object of this invention is to provide compounds, which can effectively be used as inhibitors of glucose production from the liver.
A still further object of this invention is to provide compounds, which can be effectively used as glycogen phosphorylase inhibitors.
It has now been found that members of a novel group of aromatic compounds with formula I have interesting pharmacological properties. For example, the compounds of this invention can be used in the treatment of diabetes. Especially, the compounds of this invention are active as inhibitors of glucose production from the liver. Consequently, the compounds of this invention can be used for the treatment of the increased plasma glucose levels in diabetics.
Accordingly, it is an object of the present invention to provide such novel compounds.
Further objects will become apparent from the following description.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to novel compounds of the general formula I
Figure imgf000007_0001
as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or pharmaceutically acceptable basic organic or inorganic addition salts or hydrates or prodrugs hereof, wherein A is -O-, -S-, >SO, >S02, >CO, >CR9R10, or >NR11 ;
R1 and R2 independently are one of the following groups: hydrogen, CN, -C(0)NR6R7, -COOH, -PO(OH)2, -SO2OH, tetrazole, 1-hydroxy-1 ,2-diazole, 1-hydroxytriazole, 1- hydroxyimidazole, 2-hydroxytriazole, or 1-hydroxytetrazole; when R1 or R2 is hydrogen, the other of R1 and R2 is -PO(OH)2 or -SO2OH; or R1 and R2 together may form an anhydride or an imide; R3 and R4 independently are Ci-s-alkyl, C2-8-alkenyl, C2-8-alkynyl, or C3-8-cycloalkyl, each optionally substituted with halogen, hydroxy, -SH, -SOR6, -SO2R6, -NR6R7, -NHCOR7, C1-8-alkoxy, N02, trifluoromethoxy, carbamoyl, or -CONR6R7; or R3 and R4 independently are hydrogen, halogen, perhalomethyl, C1-8-alkoxy, C1-δ-alkylthio, -SH, -SOR6, -SO2R6, trifluoromethoxy, -SO2OH, -PO(OH)2, -COOR6, -CN, hydroxy, -OCOR6, -NR6R7, -NHCOR7, -COC1-8-alkyl, -CONR6R7, -CONHSO2R7, -SO2NHR7, NO2, C1-8-alkoxycarbonyl, aryl, heteroaryl, C1-8-alkylphenyl, or tetrazole;
R5 is -CO-R8, -CH2-R8, or -CS-R8; wherein R8 is aryl, C1-8-alkyl, C2-8-alkene, phenyl- C1-8-alkyl, hetereoaryl, or C3-8-cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO2R6, NO2, -NR6R7,
-NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8-alkylthio, -COOR6, -SO2OH, -SO2CH3, -PO(OH)2, -CN, -NHCOR7, -CONHSO2R7, -SO2NHR7, C^-alkoxycarbonyl, and tetrazole; wherein
R6 and R7 independently are hydrogen, C1-8-alkyl, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, NO2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NHCO(C1-8-alkyl), C1-8-alkoxy, and trifluoromethoxy;
R9 and R10 independently are hydrogen, hydroxy, SH, halogen, or C1-8-alkyl; and
R11 is hydrogen, C1-8-alkyl, -carbonyl(Cι.8-alkyl), or phenyl-C1-8-alkyl.
In one embodiment of the present invention A is -O- or -S-, preferably A is -O-. In a second embodiment of the present invention R1 and R2 both are -COOH or CN, preferably -COOH or R1 and R2 together form an imide.
In a third embodiment of the present invention R3 is hydrogen.
In a further embodiment of the present invention R4 is hydrogen.
In one embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl, C1-8- alkyl, C2-8-alkene, phenyl-C1-8-alkyl, hetereoaryl, or C3-8-cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S02R6, NO2, -NR6R7, -NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8-alkylthio, -COOR6, -SO2OH, -PO(OH)2, -CN, -NHCOR7, -CONHSO2R7, -SO2NHR7, C1-8-alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, Cι-8-alkyl, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, -SH, -SOR6, -SO2R6, N02, NH2, NH(C1-8alkyl), N(C1.8alkyl)2, NHCO(C1-8-aikyl), C1-8-alkoxy, and trifluoromethoxy.
In a second embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl or hetereoaryl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S02R6, N02, -NR6R7, -NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8- alkylthio, -COOR6, -S02OH, -PO(OH)2, CN, -NHCOR7, -CONHSO2R7, -S02NHR7, C1-8- alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, C1-8-alkyl, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, -SH, -SOR6, -SO2R6, NO2, NH2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NHCO(C1-8-alkyl), Cι.s-alkoxy, and trifluoromethoxy.
In a third embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO2R6, NO2, -NR6R7, -NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C^- alkylthio, -COOR6, -SO2OH, -PO(OH)2, CN, -NHCOR7, -CONHSO2R7, -SO2NHR7, C1-8- alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, C1-8-alkyi, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, -SH, -SOR6, -SO2R6, NO2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NHCO(Cι-8-alkyl), C1-8-alkoxy, and trifluoromethoxy.
In a further embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, COOR6, NO2, -SO2CH3, CN, C1-8-alkyl (preferably methyl, tert-butyl, isopropyl, pentyl, heptyl), perhalomethyl (preferably trifluoromethyl), C1-8-alkoxy (preferably methoxy or ethoxy), perhalomethoxy (preferably trifluoromethoxy), C1-8-alkylthio (preferably methylthio), -CO-R6, -NR6R7, -NH-CO-R7, and -OR6; wherein R6 and R7 independently are hydrogen, Cι_s-alkyl, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, -SH, -SOR6, -SO2R6, N02, -NH(C1-8-alkyi), -N(C1-8-alkyl)2, -NHCO(C1-8-alkyl), d-β-alkoxy, and trifluoromethoxy. In a still further embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl
(preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is COOH.
In a still further embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is NO2.
In a still further embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is halogen (preferably bromo or chloro).
In a further embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -CO-R6, wherein R6 is C1-8-alkyl (preferably CH3) or substituted aryl (preferably phenyl) substituted with halogen or substituted with Ci-s-alkyl (preferably CH3).
In one embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -NH-CO-R7, wherein R7 is C1-8-alkyl (preferably CH3).
In a second embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -NR6R7, wherein R6 and R7 independently are hydrogen or C1-8-alkyl (preferably CH3). In a third embodiment of the present invention R5 is -CO-R8, wherein R8 is phenyl substituted with one or more substituents and at least one of the substituents is -OR6, wherein R6 is C1-8-alkyl (preferably methyl).
In a further embodiment of the present invention R5 is -CO-R8, wherein R8 is benzo[1 ,3]dioxole, 2,3-dihydrobenzofuran, or benzofuran, each optionally substituted with one or more substituents selected from halogen, C1-8-alkyl (preferably methyl), and C1-8- alkoxy (preferably methoxy).
The present invention relates also to novel compounds of the general formula la
Figure imgf000010_0001
la wherein R1 and R2 independently are one of the following groups: hydrogen, CN, -C(O)NR6R7,
-COOH, -PO(OH)2, -SO2OH, tetrazole, 1-hydroxy-1 ,2-diazole, 1-hydroxytriazole, 1- hydroxyimidazole, 2-hydroxytriazole, or 1-hydroxytetrazole; when R1 or R2 is hydrogen, the other of R1 and R2 is -PO(OH)2 or -SO2OH; or R1 and R2 together may form an anhydride or an imide; R5 is -CO-R8, -CH2-R8, or -CS-R8; wherein R8 is aryl, C1-8-alkyl, C2-8-alkene, phenyl-
C1-8-alkyl, hetereoaryl, or C3-8-cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO2R6, N02, -NR6R7, -NHCOR7, C1-8-alkyl, Cι_8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8-alkylthio, -COOR6, -SO2OH, -PO(OH)2, -CN, -NHCOR7, -CONHSO2R7, -SO2NHR7, d-β-alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, C^-alkyl, aryl, phenyl-C1-8-alkyl, or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, -SH, -SOR6, -SO2R6, NO2, -NH(C^-alkyl), -N(d.8-alkyl)2, -NHCO(C1-8-alkyl), C1-8- alkoxy, and trifluoromethoxy.
In a preferred embodiment of the present invention R1 and R2 are -COOH.
In another preferred embodiment of the present invention R5 is -CO-R8, wherein R8 is aryl, C1-8-alkyl, C2-8-alkene, phenyl-C^-alkyl, hetereoaryl, or C3.8-cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO2R6, NO2, -NR6R7, -NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, cabamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8-alkylthio, -COOR6, -SO2OH, -PO(OH)2, -CN, -NHCOR7, -CONHSO2R7, -SO2NHR7, C1-8-alkoxycarbonyl, and tetrazole; wherein R6 and R7 independently are hydrogen, d-8-alkyl, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, -SH, -SOR6, -SO2R6, NO2, -NH(C1-β-alkyl), -N(C1-8-alkyl)2, -NHCO(C1-8-alkyl), C1-s- alkoxy, and trifluoromethoxy.
The present invention also relates to novel compounds of the general formula lb
Figure imgf000011_0001
wherein R5 is -CO-R8, wherein R8 is aryl, C1-8-alkyl, C2-s-alkene, phenyl-C1-8-alkyl, hetereoaryl, or C3-8-cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -SO2R6, NO2, -NR6R7, -NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8-alkylthio, -COOR6, -SO2OH, -PO(OH)2, -CN, -NHCOR7, -CONHS02R7, -SO2NHR7,
Figure imgf000011_0002
and tetrazole; wherein
R6 and R7 independently are hydrogen, C1-8-alkyl, aryl, phenyl-C^-alkyl, or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, -SH, -SOR6, -SO2R6, NO2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NHCO(C1-8-alkyl), C^-alkoxy, and trifluoromethoxy.
Preferably R5 is -CO-R8, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, COOR6, N02, -SO2CH3, CN, C1-8-alkyl (preferably methyl, tertbutyl, isopropyl pentyl, heptyl), perhalomethyl (preferably trifluoromethyl), C1-8-alkoxy (preferably methoxy or ethoxy), perhalomethoxy (preferably trifluoromethoxy), C1-8-alkylthio (preferably methylthio), -CO-R6, -NR6R7, -NH-CO-R7, and -OR6; wherein R6 and R7 independently are hydrogen, C1-8-alkyl, aryl, phenyl-C1-8-alkyl or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, -SH, -SOR6, -SO2R6, NO2, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NHCO(C^-alkyl), C1-8-alkoxy, and trifluoromethoxy. Preferred compounds oof the present invention are:
4-[2-(3-dimethylaminobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-dimethylaminobenzoyl- amino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-iodobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-iodobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2-fluoro-5- thfluoromethylbenzoylamino)phenoxy]phthalic acid , 4-[2-(2-fluoro-5-trifluoromethylbenzoyl- amino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2-fluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2-fluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-acetylbenzoyl- amino)phenoxy]phthalic acid, 4-[2-(3-acetylbenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-brornobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-bromobenzoylamino)- phenoxyjphthalic acid dimethyl ester, 4-[2-(3-chlorobenzoylamino)phenoxy]phthalic acid, 4- [2-(3-chlorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2,3-difluorobenzoyl- amino)phenoxy]phthalic acid, 4-[2-(2,3-difluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2,4-difluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2,4-difluorobenzoylamino)- phenoxyjphthalic acid dimethyl ester, 4-[2-(2,5-difluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2,5-difluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(4-fluorobenzoyl- amino)phenoxy]phthalic acid, 4-[2-(4-fluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-(2-benzoylaminophenoxy)phthalic acid, 4-(2-benzoylaminophenoxy)phthalic acid dimethyl ester, 4-[2-(3-methylbenzoylamino)phenoxy]phthalic acid, 4-[2-(3-methylbenzoyl- amino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-cyanobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-cyanobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-amino-2-(3-nitro- benzoylamino)phenoxy]phthalic acid, 4-[4-amino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, N-[2-(1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yloxy)phenyl]-3-nitrobenz- amide, 4-[2-(3-aminobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-aminobenzoylamino)- phenoxyjphthalic acid dimethyl ester, 4-[4-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[4- (3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-nitrobenzoylamino)- phenylsulphenyljphthalic acid, 4-[2-(3-nitrobenzoylamino)phenylsulphenyl]phthalic acid dimethyl ester, 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-nitrobenzoylamino)- phenoxyjphthalic acid dimethyl ester, 4-[4-(4-iodobenzoylamino)-2-(3-nitrobenzoylamino)- phenoxyjphthalic acid, 4-[4-(4-iodobenzoylamino)-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-methoxycarbonyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4- [4-methoxycarbonyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4- acetylamino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[4-acetylamino-2-(3-nitro- benzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[5-fluoro-2-(3-nitrobenzoylamino)- phenoxyjphthalic acid, 4-[5-fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-bromo-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[4-bromo-2-(3-nitro- benzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-benzoylamino-2-(3-nitrobenzoyl- amino)phenoxy]phthalic acid, 4-[4-benzoylamino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[5-methyl-2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[5- methyl-2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-cyano-2-(3- nitrobenzoylamino)phenoxy]phthalic acid, 4-[4-cyano-2-(3-nitrobenzoylamino)phenoxy]- phthalic acid dimethyl ester, 4-[4,5-dichloro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4- [4,5-dichloro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[5-bromo-4- fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[5-bromo-4-fluoro-2-(3-nitrobenzoyl- amino)phenoxy]phthalic acid dimethyl ester, 4-[4-methyl-2-(3-nitrobenzoylamino)phenoxy]- phthalic acid, 4-[4-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4- fluoro-2-(3-nitrobenzoylamino)phenoxy]phthaiic acid, 4-[4-fluoro-2-(3-nitrobenzoylamino)- phenoxyjphthalic acid dimethyl ester, 4-[5-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[5-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-nitro- benzoylamino)-4-trifluoromethylphenoxy]phthalic acid, 4-[2-(3-nitrobenzoylamino)-4-trifluoro- methylphenoxyjphthalic acid dimethyl ester, 4-[2,4-bis-(3-nitrobenzoylamino)phenoxy]- phthalic acid, 4-[2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3- nitrobenzoylamino)benzyl]phthalic acid, 4-[2-(3-nitrobenzoylamino)benzyl]phthaiic acid dimethyl ester, 4-[2-(3-fluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-fluorobenzoyl- amino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-trifluoromethylbenzoylamino)phenoxy]- phthalic acid, 4-[2-(3-trifluoromethylbenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2- (3-nitrobenzylamino)phenoxy]phthalic acid, 4-[2-(3-nitrobenzylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-trifluoromethoxybenzoylamino)phenoxy]phthalic acid, 4-[2-(3-trifluoro- methoxybenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-{benzyl-[2-(3-nitrobenzoyl- amino)phenyl]amino}phthalic acid , 4-{benzyl-[2-(3-nitrobenzoylamino)phenyl]amino}phthalic acid dimethyl ester, 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-nitrobenzoyl- amino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-methoxybenzoylamino)phenoxy]phthalic acid, and 4-[2-(3-methoxybenzoylamino)phenoxy]phthalic acid dimethyl ester.
The compounds of the present invention may have one or more asymmetric centres and it is intended that stereoisomers (optical isomers), as separated, pure or partially purified stereoisomers or racemic mixtures thereof are included in the scope of the present invention. Within the present invention, the compounds of formula I, la or lb may optionally be prepared in the form of pharmaceutically acceptable basic salts or mixtures thereof, as pharmaceutically acceptable metal salts or - optionally alkylated - ammonium salts. Examples of such salts include inorganic and organic basic addition salts and the like, and include bases related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science 66, 2 (1977) and incorporated herein by reference, or lithium, sodium, potassium, magnesium and the like. The compounds of formula I, la or lb may be administered in pharmaceutically acceptable basic addition salt form or, where appropriate, as a alkali metal or alkaline earth metal or lower alkylammonium salt. Such salt forms are believed to exhibit approximately the same order of activity as the free acid forms.
Also intended as pharmaceutically acceptable addition salts are the hydrates, which the present compounds are able to form. The basic addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free acid may be dissolved in a suitable solvent containing the appropriate base, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan. Such solvates are also contemplated as being within the scope of the present invention.
The present invention relates to a compound of the above general formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof or any optical isomer thereof or a mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof for use as a medicament.
The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a compound of the above general formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof or any optical isomer thereof mixture of optical isomers, including a racemic mixture, or any tautomeric form thereof together with a pharmaceutically acceptable carrier or diluent.
In another aspect, the present invention relates to a method for the treatment of diabetes, preferably Type 2 diabetes the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention.
In a still further aspect, the present invention relates to a method for the treatment of glycogen phosphorylase dependent diseases the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention. In still another aspect, the present invention relates to a method for inhibition of glucose production from the liver, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention. In still another aspect, the present invention relates to a method for the treatment or prophylaxis of obesity or appetite regulation, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof, or of a composition according to the present invention. In still another aspect, the present invention relates to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament.
Furthermore the present invention relates to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for the treatment or prevention of diabetes, preferably Type 2 diabetes.
More particular the present invention relates to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for inhibiting the glucose production from the liver.
The present invention relates furthermore to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for inhibiting liver glycogen phosphorylase.
The present invention relates furthermore to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof for the preparation of a medicament for the treatment or prophylactic of obesity or appetite regulation. The present invention relates furthermore to the use of a compound of formula (I, la or lb) or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of hyperglycemia, hypercholesterolemia, hyperinsulinemia, atherosclerosis, hyperlipidemia or hypertension.
The term "treatment" as used herein is intended to include prophylactic treatment.
DEFINITION
In the structural formulas given herein and throughout the present specification, the following terms have the indicated meaning:
The term "optionally substituted" as used herein means that the group in question is either unsubstituted or substituted with one or more of the substituents specified. When the group in question are substituted with more than one substituent the substituent may be the same or different.
The term "halogen" means fluorine, chlorine, bromine or iodine.
The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl, or triiodomethyl.
The term "C1-8-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2- methylbutyl, 3-methylbutyl, 4-methylpentyl, neopentyl, n-pentyl, n-hexyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1 ,2,2-trimethylpropyl and the like. The term "C1-8-alkyl" as used herein also includes secondary C3-8-alkyl and tertiary C4-8-alkyl.
The term "C2-8-alkenyl" as used herein alone or in combination represents a straight or branched hydrocarbon group containing from 2 to the specified number of carbon atoms and at least one double bond. Typical C2-8-alkenyl groups include, but are not limited to, vinyl, 1- propenyl, 2-propenyl, iso-propenyl, 1 ,3-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl- 1 -propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2- hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl and the like.
The term "CM-alkynyl" as used herein alone or in combination, represents a straight or branched hydrocarbon group containing from 2 to the specified number of carbon atoms and at least one triple bond. Examples of "C2-8-alkynyl" groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3- pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 5-hexynyl, 2,4-hexadiynyl and the like.
The term "C3.8-cycloalkyl" as used herein represents a carbocyclic group having from 3 to 8 carbon atoms. Typical d-s-cycloalkyl groups include, but are not limited to, cyciopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
The term "d^-alkoxy" as used herein, alone or in combination, refers to the radical -0-d.s-alkyi where C1-8-alkyl is as defined above. Typical C^-alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, sec-butoxy, terf-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like. The term "C1-8-alkylthio" as used herein, alone or in combination, refers to a straight or branched monovalent substituent comprising a lower alkyl group linked through a divalent sulphur atom having its free valence bond from the sulphur atom and having 1 to 8 carbon atom such as e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio and the like.
The term "Cι.8-alkoxycarbonyl" as used herein refers to a monovalent substituent comprising a d_s-alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tertbutoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.
The term "phenyl-C1-8-alkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 8 carbon substituted with phenyl; such as e.g. benzyl, phenylethyl, 3-phenylpropyl and the like.
The term "C1-8-alkylphenyl" as used herein refers to phenyl substituted by C1-8-alkyl as defined above.
The term "carbamoyl" as used herein refers to NH2C(O)-.
The term "carbonyl(d.8)-alkyl" as used herein refers to carbonyl substituted by (C1-8)- alkyl as defined above.
The term "aryl" as used herein includes carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems.
The term "heteroaryl" as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; such as e.g. furyl, thienyl, pyrrolyl and the like. Heteroaryl is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below.
Examples of "aryl" and "heteroaryl" includes, but are not limited to phenyl, biphenyl, indene, fluorene, naphthyl (1-naphthyl, 2-naphthyl), anthracene (1-anthracenyl, 2- anthracenyl, 3-anthracenyl), thiophene (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, oxatriazolyl, thiathazolyl, quinazolin, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyrazolyl (1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl), triazolyl (1 ,2,3-triazol-1-yl, 1 ,2,3-triazol-4-yl 1 ,2,3-triazol-5-yl, 1 ,2,4- triazol-3-yl, 1 ,2,4-thazol-5-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isooxazolyl (isooxazo-3-yl, isooxazo-4-yl, isooxaz-5-yl), isothiazolyl (isothiazo-3-yl, isothiazo-4-yl, isothiaz-5-yl) thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyhdyl, 4- pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyhmidinyl), pyrazinyl, py dazinyl (3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4- quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2- benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3- dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6- (2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl)), benzo[b]thiophenyl (benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl), 2,3-dihydro-benzo[b]thiophenyl (2,3-dihydro- benzo[b]thiophen-2-yl, 2,3-dihydro-benzo[b]thiophen-3-yl, 2,3-dihydro-benzo[b]thiophen-4-yl, 2,3-dihydro-benzo[b]thiophen-5-yl, 2,3-dihydro-benzo[b]thiophen-6-yl, 2,3-dihydro- benzo[b]thiophen-7-yl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7- indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6- benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (2-benzoxazolyl, 3- benzoxazolyl, 4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl, 7-benzoxazolyl), benzothiazolyl (2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7- benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H- dibenz[b,f]azepine (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H- dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,fjazepine-5-yl), 10,11- dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H- dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H- dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl), benzo[1 ,3]dioxole (2- benzo[1 ,3]dioxole, 4-benzo[1 ,3]dioxole, 5-benzo[1 ,3]dioxole, 6-benzo[1 ,3]dioxole, 7- benzo[1 ,3]dioxole), and tetrazolyl (5-tetrazolyl, N-tetrazolyl).
The present invention also relates to partly or fully saturated analogues of the ring systems mentioned above.
Certain of the above defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other.
PHARMACEUTICAL COMPOSITIONS
In another aspect, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of the general formula (I, la or lb) or a pharmaceutically acceptable salt or prodrug or hydrate thereof together with a pharmaceutically acceptable carrier or diluent.
Optionally, a pharmaceutical composition of the present invention may comprise a compound of formula (I, la or lb) combined with one or more compounds.
Pharmaceutical compositions containing a compound according to the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy, 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
Typical compositions include a compound of formula (I, la or lb) or a pharmaceutically acceptable basic addition salt or prodrug or hydrate thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material, which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the present invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
The route of administration may be any route, which effectively transports the active compound of formula (I, la or lb) to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
For nasal administration, the preparation may contain a compound of formula I, la or lb dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed. A typical tablet which may be prepared by conventional tabletting techniques may contain:
Core:
Active compound (as free compound or salt thereof) 250 mg
Colloidal silicon dioxide (Aerosil)® 1.5 mg
Cellulose, microcryst. (Avicel)® 70 mg
Modified cellulose gum (Ac-Di-Sol)® 7.5 mg
Magnesium stearate Ad.
Coating:
HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg
*Acylated monogiyceride used as plasticizer for film coating.
The compounds of the present invention may be administered to a mammal, especially a human, in need of such treatment, prevention, elimination, alleviation or amelioration of the various diseases as mentioned above, e.g. hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlioidemla or obesity, and especially diabetes. Such mammals also include animals, both domestic animals, e.g. household pets, and non- domestic animals such as wildlife.
The compounds of the present invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day may be used. A most preferable dosage is about 0.5 mg to about 250 mg per day. In choosing a regimen for patients it may frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in harge.
Generally, the compounds of the present invention are dispensed in unit dosage form comprising from about 0.05 to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
Usually, dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.05 mg to about 1000 mg, preferably from about 0.5 mg to about 250 mg of the compounds of formula I, la or lb admixed with a pharmaceutically acceptable carrier or diluent. The present invention also encompasses prodrugs of a compound according to the invention which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of a compound according to the present invention which are readily convertible in vivo into a compound according to the present invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. The ester derivatives of formula I, la or lb could be suitable prodrugs.
The present invention also encompasses active metabolites of a compound according to the invention. In a further aspect of the present invention a compound according to the invention may be administered in combination with further pharmacologically active substances e.g. other antiobesity agents or appetite regulating agents.
Such agents may be selected from the group consisting of CART agonists, NPY antagonists, MC4 agonists, orexin antagonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK agonists, serotonin re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, GLP-1 , leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR β agonists.
In a preferred embodiment of the present invention the antiobesity agent is leptin.
In another preferred embodiment the antiobesity agent is dexamphetamine or amphetamine.
In another preferred embodiment the antiobesity agent is dexfenfluramine. In still another preferred embodiment the antiobesity agent is sibutramine.
In a further preferred embodiment the antiobesity agent is orlistat. In another preferred embodiment the antiobesity agent is mazindol or phentermine. In a further aspect of the present invention a compound according to the invention may be administered in combination with further pharmacologically active substances e.g. other lipid lowering agents. A compound according to the present invention may also be administered in combination with an antidiabetic or other pharmacologically active material, including compounds for the treatment and/or prophylaxis of insulin resistance and diseases, wherein insulin resistance is the pathophysiological mechanism. Suitable antidiabetics comprise insulin, GLP-1 derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference, as well as orally active hypoglycaemic agents. The orally active hypoglycaemic agents preferably comprise sulphonylureas, biguanides, oxadiazolidinediones, thiazolidinediones, α-glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S, which are incorporated herein by reference, insulin sensitizers, hepatic enzyme inhibitors, glucose uptake modulators, compounds modifying the lipid metabolism, compounds lowering food intake, PPAR and RXR agonists and agents acting on the ATP-dependent potassium channel of the β-cells.
In a preferred embodiment of the present invention a compound according to the invention is administered in combination with insulin. In a further preferred embodiment a compound according to the present invention is administered in combination with a sulphonylurea such as e.g.tolbutamide, glibenclamide, glipizide or glicazide.
In another preferred embodiment a compound according to the present invention is administered in combination with a biguanidine such as e.g. metformin. In still another preferred embodiment a compound according to the present invention is administered in combination with a thiazolidinedione such as e.g. troglitazone, ciglitazone, pioglitazone, rosiglitazone and the compounds disclosed in WO 97/41097 to Dr. Reddy's Research Foundation, especially 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2- quinazolinylmethoxy]phenyl]-methyl]-2,4-thiazolidinedione. In a further preferred embodiment a compound according to the present invention is administered in combination with an α-glucosidase inhibitor such as e.g. voglibose or acarbose.
In yet a preferred embodiment a compound according to the present invention is administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells such as e.g. tolbutamide, glibenclamide, glipizide, glicazide or repaglinide. Furthermore, a compound according to the present invention may be administered in combination with an antihypertensive agent. Examples of antihypertensive agents are β- blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy,19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. Any novel feature or combination of features described herein is considered essential to this invention.
METHODS
In the Method and Examples the following terms are intended to have the following, general meaning: Abbreviations:
DMF : N,N-dimethylformamide
THF : tetrahydrofuran
NMP : N-methylpyrrolidone
DMSO : dimethylsulphoxide TEA : triethylamine
DMAP : 4-dimethylaminopyridine
Ph : phenyl
HOBt : N-hydroxybenzotriazole
EDAC : N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide Ts : Tosyl
Mp : Melting point
The present invention also relates to methods of preparing the above-mentioned compounds.
The preparation of the compounds according to the present invention can be realized in many ways. These methods comprise:
1a) Reacting a compound of formula II with a compound of formula III in a solvent such as acetone, DMF, THF, NMP, DMSO, CH2CI2 with a base such as NaOH, LiOH, TEA,
DMAP, K2CO3, sodium hydride, potassium tert-butoxide, or sodium tert-butoxide to form a compound of formula IV.
Figure imgf000024_0001
A is O or S. Lg is a leaving group such as F, Cl, Br, I, NO2, -OSO2CH3 or -OTs.
R1 , R2, R3 and R4 have the meanings set forth above. When R1 , R2, R3, and R4 are labile groups e.g. acids or hydroxy they are protected as well known derivatives such as carboxylic esters, sulphonic esters, phosphoric esters, nitrile, amides, or cyclic anhydrides or cyclic amides or as e.g. ethers.
When A is >CO the compound is made by Friedel Craft acylation.
Figure imgf000024_0002
Mb Nib IVb
Mb and 11 lb are reacted in a aprotic solvent such as CS2 with a Friedel Craft catalyst such as AICI3, FeCI3, SnCI4 or ZnCI2 to make IVb as described in J.Org.Chem. 48(13) 2281- 2285 (1983) or Justus Liebigs. Ann. Chem. 220, 250 (1993). Both references are incorporated herein by reference.
When A is >CR9R10 the reaction can be made by cross coupling or Grignard coupling.
Figure imgf000024_0003
lie
X is B(OH)2, Cl, Br, I, CIMg-, BrMg-, or IMg- as described in Synthetic Commun. V\_, 513 (1981 ), Tetrahedron 54(12), 2953-2966 (1998), J.Chem.Soc.Chem.Com. 3, 305-306 (1995), J.Amer.Chem.Soc. 18(42), 10220-10227 (1996) or J.Chem.Soc.Perk.Trans. 1(6) 719-730 (1993) all incorporated herein by reference.
If A in lie is a >CO and X is H this reaction can be performed as a Friedel Craft coupling as described above, under Friedel Craft conditions described above. R1 , R2, R3, R4 and R8 have the meanings set forth above. When R1 , R2, R3 and R4 are labile groups e.g. acids or hydroxy, they are protected as well known derivatives such as carboxylic esters, sulphonic esters, phosphoric esters, nitrile, amides, or cyclic anhydrides or cyclic amides or as e.g. ethers.
1 b) Reacting a compound of formula V with a compound of formula VI in a solvent such as mentioned above with a base such as mentioned above to produce a compound of formula VII.
Figure imgf000025_0001
V VI VII
A is O, S, or N and Lg, R1 , R2, R3, and R4 have the meaning set forth above. Compounds of formula VII can be reduced by catalytic hydrogenation, H2,Pd/C, to form compound IV.
2a) Reacting compound of formula IV with a compound of formula VIII in a solvent such as acetone, DMF, THF, CH2CI2 or NMP with TEA, NaOH, LiOH, DMAP, K2C03, sodium tert- butoxide or potassium tert-butoxide as base to produce a compound of formula IX.
Figure imgf000025_0002
IX wherein A, R1 , R2, R3, R4, and R8 have the meaning set forth above.
2b) A compound of formula IX can be synthesised from the R8-CO2H and the amine IV by coupling with HOBt, EDAC and TEA in a solvent such as DMF, CH2CI2 or NMP to produce compounds of formula IX.
A compound of formula IV can be reacted with a compound of formula X like Y-CH2R8, wherein Y is a leaving group such as Cl, Br, I, -OS02CH3, or -OTs, to produce a compound of formula XI in a solvent such as acetone, DMF, DMSO, THF, NMP or CH2CI2 with a base such as NaOH, LiOH, K2C03, TEA, DMAP, sodium tert-butoxide, or potassium tert-butoxide.
Figure imgf000026_0001
wherein A, R1 , R2, R3, R4, and R8 have the meaning set forth above.
3a) Reacting a compound of formula (XIII), wherein A is O or S, and R2 and R3 have the meaning set forth above with a compound of the general formula (XII), wherein Su is a substrate and L is a linker to form a compound of the general formula (XIV):
Figure imgf000026_0002
(XIII) (XIV)
3b) Reacting a compound of formula (XIV) with a compound of formula (V) to form a compound of formula (XV), wherein A is O or S and Lg, L, Su, R2, R3, and R4 have the meaning set forth above or wherein A is C the AH group is CR6R7Br and Lg are Sn(Me)3 or B(OH)2 WO95/04277 (1995) or J.Am.Chem.Soc. 116, 11171 -11172 (1994).
Figure imgf000026_0003
(XIV) (V) (XV)
3c) Reducing a compound of formula (XV) to form a compound of formula (XVI) and reacting this compound with R8-COOH to produce a compound of formula (XVII):
Figure imgf000026_0004
3d) Cleavage of a compound of formula (XVII) by e.g. treatment with a strong acid to form a compound of formula (I), wherein A is O, S or CR6R7, R1 is carboxylic acid, and R2, R3, R4, and R5 have the meaning set forth above.
The substrate Su may be any insoluble or partially insoluble material, to which compounds may be covalently attached. Substrates may be selected from the group consisting of any kind of organic or inorganic polymeric or oligomeric compound. Preferably the substrate may be selected from the groups consisting of polystyrene, polyethylene glycol (PEG), polyethylene glycol attached to polystyrene, polyacrylamides, polyamides, polysaccharides and silicates. Depending on the type of substrate chosen, different types of solvents or protecting groups may be used.
The linker L is a molecule with at least two reactive sites, which permit its covalent attachment to other molecules or to a substrate. Either the bond of the linker to the substrate or the bond of the linker to other molecules attached to it or the linker itself must be cleavable upon selective exposure to an activator such as a selected chemical activator or other specific conditions, e.g. by treatment with a strong acid or by exposure to electromagnetic radiation or by metal catalysis;
The starting materials employed in the synthesis of the compounds from formula II, III, V, VI and VIII are either known or may be prepared in conventional manner from commercially available materials, e.g according to the methods described in the examples. Other compounds of the general formula I can be prepared by the above strategy. A variety of functional groups can be introduced in the compounds prepared as outlined above by methods well known to those skilled in the art.
The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the present invention in diverse forms thereof.
EXAMPLES
Example 1
4-f2-(3-Nitrobenzoylamino)phenoxy1phthalic acid (Compound 1 ) To a suspension of Wang resin (1 g, 0.92 mmol, Bachem, loading: 0.92 mmol/g) in a mixture of methylene chloride (5 ml) and DMF (5 ml) were added 4-hydroxyphthalic acid (1.7 g, 9.3 mmol), diisopropyl carbodiimide (1.4 ml, 9.0 mmol) and 4-dimethylaminopyridine (66 mg, 0.54 mmol). The mixture was shaken for 20 hours and filtered. The resin was washed with DMF (4x10 ml), methylene chloride (4x10 ml), methanol (4x10 ml), and methylene chloride (4x10 ml). The resin was dried in vacυo. o-Fluoronitrobenzene (0.4 ml, 3.77 mmol) and 0.5 M potassium bis(trimethylsilyl)amide (1.2 ml, 0.6 mmol) were added to a suspension of the dried resin in DMF (4 ml). The mixture was shaken for 24 hours under a nitrogen atmosphere, filtered and the resin was washed with DMF (4x5 ml), methylene chloride (4x5 ml), DMF (4x5 ml), and N-methylpyrrolidone (4x5 ml). A solution of stannochloride, dihydrate (0.9 g, 3.99 mmol) in N-methylpyrrolidone (4 ml) was added to the resin. The mixture was shaken for 24 hours, filtered and washed with N-methylpyrrolidone (4x5 ml), methylene chloride (4x5 ml), and methanol (4x5 ml). The resin was dried in vacυo to give approx. 244 mg material.
To a suspension of this resin (20 mg, 0.0184 mmol) in a mixture of DMF (1 ml) and methylene chloride (1 ml) were added 3-nitrobenzoic acid (30 mg, 0.180 mmol) and diisopropyl carbodiimide (12 μl, 0.077 mmol). The mixture was shaken for 24 hours, filtered and the resin washed with DMF (4x4 ml), THF (4x4 ml), and methylene chloride (4x4 ml). The resin was shaken with methylene chloride: trifluoro methane (1 :1 ) (2 ml) for 20 minutes. The mixture was filtered and the resin washed with tetrachloro methane (4 ml) and the collected filtrates were evaporated to dryness in vacυo to give 4-[2-(3-nitrobenzoylamino)- phenoxyjphthalic acid (5.5 mg, yield: 70%) as light crystals. 1H-NMR (DMSO-d6) in ppm: δ 10.3 (s, 1 H), 8.58 (m, 1 H), 8.38 (m, 1 H), 8.18 (d, 1 H), 7.6-7.8 (m, 3H), 7.3-7.4 (m, 2H), 7.18 (d.d., 1 H), 7.1 (m, 1 H), 7.07 (d.d., 1 H). LC-MS: m/e 223 (MH+), 205 (MH+ - H20).
In a similar way the following compounds were prepared:
4-(2-r2-(2-Carboxyphenyl)acetylaminolphenoxy)phthalic acid (Compound 2) was prepared according to the method described above using homophthalic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 436 (MH+)
4-r2-(2-Bromobenzoylamino)phenoxylphthalic acid (Compound 3) was prepared according to the method described above using 2-bromobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 456/458 (MH+), 438/440 (MH+ - H20).
4-[2-(2-Chlorobenzoylamino)phenoxy1phthalic acid (Compound 4) was prepared according to the method described above using 2-chiorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 412 (MH+), 394 (MH+ - H20). 4-r2-(4-Chlorobenzoylamino)phenoxylphthalic acid (Compound 5) was prepared according to the method described above using 4-chlorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 412 (MH+), 394 (MH+ - H20). 4-r2-(3-Methoxybenzoylamino)phenoxy1phthalic acid (Compound 6) was prepared according to the method described above using 3-methoxybenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 408 (MH+), 390 (MH+ - H2O).
4-r2-(2-Carboxybenzoylamino)phenoxylphthalic acid (Compound 7) was prepared according to the method described above using phthalic acid instead of 3- nitrobenzoic acid. LC-MS: m/e 422 (MH+).
4-r2-(2-Methoxybenzoylamino)phenoxylphthalic acid (Compound 8) was prepared according to the method described above using 2-methoxybenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 408 (MH+), 390 (MH+ - H2O).
4-f2-(4-Acetylaminobenzoylamino)phenoxylphthalic acid (Compound 9) was prepared according to the method described above using 4-acetamidobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 435 (MH+), 417 (MH+ - H2O).
4-f2-(4-Methoxybenzoylamino)phenoxylphthalic acid (Compound 10) was prepared according to the method described above using 4-methoxybenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 408 (MH+), 390 (MH+ - H20). 4-f2-(3,4,5-Trimethoxybenzoylamino)phenoxylphthalic acid (Compound 11 ) was prepared according to the method described above using 3,4,5-trimethoxybenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 468 (MH+), 450 (MH+ - H20).
4-(2-f(Naphthalene-1-carbonyl)aminolphenoxy}phthalic acid (Compound 12) was prepared according to the method described above using 1-naphthoic acid instead of 3- nitrobenzoic acid. LC-MS: m/e 428 (MH+), 410 (MH+ - H20). 4-{2-r(Naphthalene-2-carbonyl)aminolphenoxy}phthalic acid (Compound 13) was prepared according to the method described above using 2-naphthoic acid instead of 3- nitrobenzoic acid.
LC-MS: m/e 428 (MH+), 410 (MH+ - H20). 4-r2-(2-Acetylbenzoylamino)phenoxylphthalic acid (Compound 14) was prepared according to the method described above using 2-acetyl benzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 420 (MH+).
4-r2-(4-Ethoxybenzoylamino)phenoxylphthalic acid (Compound 15) was prepared according to the method described above using 4-ethoxybenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 422 (MH+), 404 (MH+- H2O).
4-(2-r(BenzoH .31dioxole-5-carbonyl)aminolphenoxy)phthalic acid (Compound 16) was prepared according to the method described above using piperonylic acid instead of 3- nitrobenzoic acid.
LC-MS: m/e 422 (MH+), 404 (MH+- H2O).
4-r2-(2,5-Dichlorobenzoylamino)phenoxylphthalic acid (Compound 17) was prepared according to the method described above using 2,5-dichlorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 446 (MH+), 428 (MH+ - H20).
4-r2-(4-Bromobenzoylamino)phenoxylphthalic acid (Compound 18) was prepared according to the method described above using 4-bromobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 456/458 (MH+), 438/440 (MH+ - H20). 4-r2-(3-Dimethylaminobenzoylamino)phenoxy1phthalic acid (Compound 19) was prepared according to the method described above using 3-dimethylaminobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 421 (MH+), 403 (MH+ - H20).
4-r2-(4-Trifluoromethoxybenzoylamino)phenoxylphthalic acid (Compound 20) was prepared according to the method described above using 4-trifluoromethoxybenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 462 (MH+), 444 (MH+ - H20). 4-r2-(3,5-Dimethoxybenzoylamino)phenoxylphthalic acid (Compound 21 ) was prepared according to the method described above using 3,5-dimethoxybenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 438 (MH+), 420 (MH+ - H2O). 4-F2-(5-Chloro-2-methoxybenzoylamino)phenoxylphthalic acid (Compound 22) was prepared according to the method described above using 5-chioro-2-methoxybenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 442 (MH+), 424 (MH+ - H2O).
4-r2-(3.4-Difluorobenzoylamino)phenoxylphthalic acid (Compound 23) was prepared according to the method described above using 3,4-difluorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 414 (MH+), 396 (MH+ - H2O).
4-r2-(2-lodobenzoylamino)phenoxylphthalic acid (Compound 24) was prepared according to the method described above using 2-iodobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 504 (MH+), 486 (MH+ - H2O).
4-r2-(2.4-Dimethoxybenzoylamino)phenoxylphthalic acid (Compound 25) was prepared according to the method described above using 2,5-dimethoxybenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 438 (MH+), 420 (MH+ - H2O).
4-r2-(3-lodobenzoylamino)phenoxylphthalic acid (Compound 26) was prepared according to the method described above using 3-iodobenzoic acid instead of
3-nitrobenzoic acid.
LC-MS: m/e 504 (MH+), 486 (MH+ - H2O). 4-r2-(3,5-Dimethylbenzoylamino)phenoxylphthalic acid (Compound 27) was prepared according to the method described above using 3,5-dimethylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 406 (MH+), 388 (MH+ - H2O).
4-{2-r2-(4-Chlorobenzoyl)benzoylaminolphenoxy)phthalic acid (Compound 28) was prepared according to the method described above using 4-(chlorobenzoyl)benzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 516 (MH+), 498 (MH+ - H20). 4-{2-|"2-(4-Fluorobenzoyl)benzoylamino1phenoxy)phthalic acid (Compound 29) was prepared according to the method described above using 4-(fluorobenzoyl)benzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 500 (MH+), 482 (MH+ - H20). 4-r2-(2-Chloro-4-fluorobenzoylamino)phenoxylphthalic acid (Compound 30) was prepared according to the method described above using 2-chloro-4-fluorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 430 (MH+), 412 (MH+ - H2O).
4-(2-f(2,3-Dihvdrobenzofuran-7-carbonyl)aminolphenoxy>phthalic acid (Compound 31 ) was prepared according to the method described above using 7-(2,3-dihydrobenzofuranyl)- carboxylic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 420 (MH+), 402 (MH+ - H20).
4-[2-(4-tert-Butylbenzoylamino)phenoxylphthalic acid (Compound 32) was prepared according to the method described above using 4-tert-butylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 434 (MH+), 416 (MH+ - H20).
4-r2-(3,4-Dichlorobenzoylamino)phenoxylphthalic acid (Compound 33) was prepared according to the method described above using 3,4-dichlorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 446 (MH+), 428 (MH+ - H20).
4-r2-(2-Fluoro-5-trifluoromethylbenzoylamino)phenoxy1phthalic acid (Compound 34) was prepared according to the method described above using 2-fluoro-5-trifluorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 464 (MH+), 446 (MH+ - H20). 4-r2-(2-Fluorobenzoylamino)phenoxylphthalic acid (Compound 35) was prepared according to the method described above using 2-fluorobenzoic acid instead of
3-nitrobenzoic acid.
LC-MS: m/e 396 (MH+), 378 (MH+ - H20).
4-r2-(3-Benzoyl-benzoylamino)phenoxylphthalic acid (Compound 36) was prepared according to the method described above using benzophenone-3-carboxylic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 482 (MH+), 464 (MH+ - H20). 4-(2-r2-(4-Methylbenzoyl)benzoylaminolphenoxy}phthalic acid (Compound 37) was prepared according to the method described above using 2-(4-toloyl)benzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 496 (MH+), 478 (MH+ - H20). 4-l"2-(3-Acetylbenzoylamino)phenoxylphthalic acid (Compound 38) was prepared according to the method described above using 3-acetylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 420 (MH+), 402 (MH+ - H2O).
4-f2-(2,3-Dimethoxybenzoylamino)phenoxylphthalic acid (Compound 39) was prepared according to the method described above using 2,3-dimethoxybenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 438 (MH+), 420 (MH+ - H2O).
4-r2-(2-Benzylbenzoylamino)phenoxylphthalic acid (Compound 40) was prepared according to the method described above using α-phenyl-o-toluic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 468 (MH+), 450 (MH+ - H2O).
4- 2-r(5-Methoxy-2-methyl-2,3-dihvdrobenzofuran-7-carbonyl)aminolphenoxy}phthalic acid (Compound 41 ) was prepared according to the method described above using 2-methyl-5-methoxy-2,3- dihydrobenzo(b)furan-7-carboxylic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 464 (MH+), 446 (MH+ - H20).
4-F2-(4-Methyl-benzoylamino)phenoxylphthalic acid (Compound 42) was prepared according to the method described above using p-toluic acid instead of 3- nitrobenzoic acid. LC-MS: m/e 392 (MH+), 374 (MH+ - H20).
4-(2-r(4-Chloro-2-methyl-2,3-dihvdrobenzofuran-7-carbonyl)aminolphenoxy}phthalic acid (Compound 43) was prepared according to the method described above using 2-methyl-4-chloro-2,3- dihydrobenzo(b)furan-7-carboxylic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 468 (MH+), 450 (MH+ - H20).
4-{2-r(2-Methylbenzofuran-7-carbonyl)aminolphenoxy)phthalic acid (Compound 44) was prepared according to the method described above using 2-methylbenzo(b)furan-7- carboxylic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 432 (MH+), 414 (MH+ - H20). 4-r2-(4-lodobenzoylamino)phenoxylphthalic acid (Compound 45) was prepared according to the method described above using 4-iodobenzoic acid instead of
3-nitrobenzoic acid.
LC-MS: m/e 504 (MH+), 486 (MH+ - H20). 4-f2-(5-Bromo-2-methoxybenzoylamino)phenoxylphthalic acid (Compound 46) was prepared according to the method described above using 2-methoxy-5-bromobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 486/488 (MH+), 468/470 (MH+- H2O).
4-r2-(2-Benzyloxy-5-chlorobenzoylamino)phenoxylphthalic acid (Compound 47) was prepared according to the method described above using 2-benzyloxy-5-chlorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 518 (MH+), 500 (MH+- H20).
4-r2-(3-Bromobenzoylamino)phenoxylphthalic acid (Compound 48) was prepared according to the method described above using 3-bromobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 456/458 (MH+), 438/440 (MH+- H2O).
4-r2-(3-Chlorobenzoylamino)phenoxy1phthalic acid (Compound 49) was prepared according to the method described above using 3-chlorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 412 (MH+), 394 (MH+ - H2O).
4-r2-(3,4,5-Tribromobenzoylamino)phenoxylphthalic acid (Compound 50) was prepared according to the method described above using 3,4,5-tribromobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 612, 614, 616, 618 (1 :3:3:1) (MH+), 594, 596, 598, 600 (1 :3:3:1) (MH+- H2O). 4-r2-(3,5-Dibromobenzoylamino)phenoxylphthalic acid (Compound 51 ) was prepared according to the method described above using 3,5-dibromobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 534, 536, 538 (1 :2:1 ) (MH+), 516, 518, 520 (1 :2:1 ) (MH+ - H20).
4-r2-(4-Methanesulphonylbenzoylamino)phenoxylphthalic acid (Compound 52) was prepared according to the method described above using 4-methylsulphonylbenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 456 (MH+), 438 (MH+ - H20). 4-f2-(3.4-Dimethylbenzoylamino)phenoxylphthalic acid (Compound 53) was prepared according to the method described above using 3,4-dimethylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 406 (MH+), 388 (MH+ - H20). 4-[2-(3,5-Dichlorobenzoylamino)phenoxylphthalic acid (Compound 54) was prepared according to the method described above using 3,5-dichlorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 446 (MH+), 428 (MH+ - H20).
4-r2-(2-Bromo-4-fluorobenzoylamino)phenoxylphthalic acid (Compound 55) was prepared according to the method described above using 2-bromo-4-fluorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 474, 476 (MH+), 456, 458 (MH+ - H2O).
4-r2-(2-Chloro-6-fluorobenzoylamino)phenoxylphthalic acid (Compound 56) was prepared according to the method described above using 2-chloro-6-fluorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 430 (MH+), 412 (MH+- H2O).
4-f2-(2.6-Difluoro-benzoylamino)phenoxylphthalic acid (Compound 57) was prepared according to the method described above using 2,6-difluorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 414 (MH+), 396 (MH+ - H20).
4-r2-(4-lsopropylbenzoylamino)phenoxy1phthalic acid (Compound 58) was prepared according to the method described above using 4-isopropylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 420 (MH+), 402 (MH+- H20). 4-r2-(4-n-Pentylbenzoylamino)phenoxylphthalic acid (Compound 59) was prepared according to the method described above using 4-n-pentylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 448 (MH+), 430 (MH+ - H20).
4-r2-(4-n-Heptylbenzoylamino)phenoxylphthalic acid (Compound 60) was prepared according to the method described above using 4-n-heptylbenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 476 (MH+), 458 (MH+ - H20). 4-r2-(4-Trifluoromethylbenzoylamino)phenoxylphthalic acid (Compound 61 ) was prepared according to the method described above using 4-trifluoromethylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 446 (MH+), 428 (MH+ - H20). 4-r2-(5-Bromo-2-chlorobenzoylamino)phenoxylphthalic acid (Compound 62) was prepared according to the method described above using 2-bromo-2-chlorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 490, 492 (MH+), 472, 474 (MH+ - H2O).
4-r2-(2.3-Difluorobenzoylamino)phenoxylphthalic acid (Compound 63) was prepared according to the method described above using 2,3-difluorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 414 (MH+), 396 (MH+ - H2O).
4-r2-(4-Bromo-2-chlorobenzoylamino)phenoxylphthalic acid (Compound 64) was prepared according to the method described above using 4-bromo-2-chlorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 490, 492 (MH+), 472, 474 (MH+- H2O).
4-r2-(2-Chloro-5-iodobenzoylamino)phenoxylphthalic acid (Compound 65) was prepared according to the method described above using 2-chloro-5-iodobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 538 (MH+), 520 (MH+ - H2O).
4-r2-(4-Methylthiobenzoylamino)phenoxylphthalic acid (Compound 66) was prepared according to the method described above using 4-methylthiobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 424 (MH+), 406 (MH+ - H20). 4-[2-(2,4-Difluorobenzoylamino)phenoxylphthalic acid (Compound 67) was prepared according to the method described above using 2,4-difluorobenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 414 (MH+), 396 (MH+ - H20).
4-r2-(2,5-Difluorobenzoylamino)phenoxylphthalic acid (Compound 68) was prepared according to the method described above using 2,5-difluorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 414 (MH+), 396 (MH+- H20). 4-r2-(4-Fluorobenzoylamino)phenoxylphthalic acid (Compound 69) was prepared according to the method described above using 4-fluorobenzoic acid instead of
3-nitrobenzoic acid.
LC-MS: m/e 396 (MH+), 378 (MH+ - H20). 4-(2-Benzoylaminophenoxy)phthalic acid (Compound 70) was prepared according to the method described above using benzoic acid instead of 3- nitrobenzoic acid.
LC-MS: m/e 378 (MH+), 360 (MH+ - H2O).
4-r2-(2,4-Dichlorobenzoylamino)phenoxylphthalic acid (Compound 71 ) was prepared according to the method described above using 2,4-dichlorobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 446 (MH+), 428 (MH+ - H2O).
4-r2-(3-Methylbenzoylamino)phenoxylphthalic acid (Compound 72) was prepared according to the method described above using 3-methylbenzoic acid instead of 3-nitrobenzoic acid.
LC-MS: m/e 392 (MH+), 374 (MH+ - H2O).
4-r2-(3-Cvanobenzoylamino)phenoxylphthalic acid (Compound 73) was prepared according to the method described above using 3-cyanobenzoic acid instead of 3-nitrobenzoic acid. LC-MS: m/e 403 (MH+), 385 (MH+ - H2O).
4-f4-Amino-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 74) was prepared according the method described above using N-(tert-butoxycarbonyl)-4-fluoro- 3-nitroaniline instead of o-fluoronitrobenzene. LC-MS: m/e 438 (MH+), 420 (MH+ - H20). 1H-NMR (D6-DMSO) in ppm: δ 10.1 (1 H,s), 8.5 (1 H,s), 8.3 (1 H,d.d.), 8.1 (1 H,d), 7.70 (1 H,t), 7.67 (1 H,d), 6.97 (3H,d.d.), 6.91 (1 H,d), 6.6 (1 H,d.d.).
4-r2-(2-Thiophen-2-yl-acetylamino)phenoxylphthalic acid (Compound 75) was prepared according the method described above using 2-thienylacetic acid instead of 3- nitrobenzoic acid. 1H-NMR (D6-DMSO) in ppm: δ 9.67 (1 H,s), 7.98 (1 H,d), 7.73 (1 H,d), 7.32 (1 H,d), 7.23 (2H,p), 7.09 (2H,m), 7.03 (1 H,d.d.), 6.91 (1 H,d), 6.85 (1 H,d).
4-(2-f(Furan-2-carbonyl)aminolphenoxy}phthalic acid (Compound 76) was prepared according the method described above using 2-furoic acid instead of 3- nitrobenzoic acid. 1H-NMR (De-DMSO) in ppm: δ 9.5 (1 H,s), 7.85 (1 H,s), 7.7-7.8 (2H,m), 7.25-7.32 (2H,m), 7.22 (1 H,d), 7.1-7.15 (3H,m), 6.65 (1 H,d).
4-r2,4-Bis-(3-nitrobenzoylamino)phenoxy1phthalic acid (Compound 77) was prepared according the method described above using 1-fluoro-2,4-dinitrobenzene instead of o-fluoronitrobenzene.
LC-MS: m/e 609 (M+Na), 604 (M+NH4 +), 569 (MH+- H2O).
1H-NMR (De-DMSO) in ppm: δ 10.8 (1H,s); 10.5 (1 H,s); 8.83 (1 H,t); 8.56 (1 H,t); 8.36-8.49
(3H,m); 8.24 (1 H,d); 8.18 (1 H,d); 7.87 (1H,t); 7.72-7.8 (3H,m); 7.24 (1H,d), 7.09 (2H,d.d.).
4-r2-(3-Nitrobenzoylamino)-4-trifluoromethylphenoxylphthalic acid (Compound 78) was prepared according the method described above using 1-fluoro-2-nitro-4- trifluoromethylbenzene instead of o-fluoronitrobenzene. LC-MS: m/e 513 (M+Na), 491 (M+NH4 +), 473 (MH+ - H2O).
1H-NMR (De-DMSO) in ppm: δ 10.58 (1 H,s); 8.64 (1 H,s); 8.43 (1 H,d.d.); 8.25 (1 H,d); 8.17 (1H,s); 7.74-7.84 (2H,m); 7.68 (1 H,d.d.), 7.31 (1 H,d); 7.19-7.27 (2H,m). 4-[5-Methyl-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 79) was prepared according the method described above using 2-fluoro-1-nitro-4-methylbenzene instead of o-fluoronitrobenzene.
LC-MS: m/e 459 (M+Na), 419 (MH+ - H20). H-NMR (De-DMSO) in ppm: δ 10.26 (1 H,s); 8.55 (1 H,s); 8.38 (1 H,d.d.); 8.17 (1H,d); 7.48 (1H,t); 7.7 (1 H,d); 7.58 (1 H,d); 7.17 (1 H,d.d.); 7.05-7.1 (2H,m); 7.0 (1 H,s); 2.8 (3H,s).
4-[4-Fluoro-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 80) was prepared according the method described above using 1 ,4-difiuoro-2-nitrobenzene instead of o-fluoronitrobenzene. LC-MS: m/e 463 (M+Na), 441 (MH+), 423 (MH+- H20). 1H-NMR (D6-DMSO) in ppm: δ 10.44 (1 H,s); 8.54 (1H,t); 8.39 (1 H,d.d.); 8.15 (1H,d); 7.76 (1 H,t); 7.65-7.73 (2H,m); 7.27 (1 H,d.d.); 7.19 (1 H,d.d.); 7.05-7.1 (2H,m).
4-r4-Methyl-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 81) was prepared according the method described above using 1-fluoro-2-nitro-4-methylbenzene instead of o-fluoronitrobenzene. LC-MS: m/e 459 (M+Na), 437 (MH+), 419 (MH+ - H20).
1H-NMR (D6-DMSO) in ppm: δ 10.28 (1 H,s); 8.55 (1 H,s); 8.38 (1 H,d); 8.16 (1 H,d); 7.75 (1 H,t); 7.7 (1 H,d); 7.5 (1 H,s); 7.17 (1 H,d); 7.0-7.1 (3H,m); 2.8 (3H,s). 4-r5-Bromo-4-fluoro-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 82) was prepared according the method described above using 5-bromo-1 ,4-difluoro-2- nitrobenzene instead of o-fluoronitrobenzene. LC-MS: m/e 519/521 (MH+), 501/503 (MH+ - H20). 4-r4-Methanesulfonyl-2-(3-nitrobenzoylamino)phenoxy1phthalic acid (Compound 83) was prepared according the method described above using 4-fluoro-3-nitrophenyl methyl sulfone instead of o-fluoronitrobenzene.
4-f4.5-Dichloro-2-(3-nitrobenzoylamino)phenoxy1phthalic acid (Compound 84) was prepared according the method described above using 1 ,2-dichloro-4-fluoro-5- nitrobenzene instead of o-fluoronitrobenzene. H-NMR (D6-DMSO) in ppm: δ 10.53 (1 H,s); 8.55 (1 H,s); 8.4 (1 H,d.d.); 8.16 (1 H,d); 8.06 (1H,s); 7.77 (1 H,d); 7.74 (1 H,d); 7.52 (1 H,s); 7.12-7.20 (2H,m).
4-r4-Cyano-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 85) was prepared according the method described above using 4-fluoro-3-nitrobenzonitrile instead of o-fluoronitrobenzene.
1H-NMR (D6-DMSO) in ppm: δ 10.58 (1H,s); 8.6 (1 H,t); 8.41 (1 H,d.d.); 8.18-8.24 (2H,m); 7.78 (2H,d); 7.75 (1 H,d.d.); 7.28 (1 H,d), 7.2-7.25 (2H,m).
4-r5-Methyl-2,4-bis-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 86) was prepared according the method described above using 5-fluoro-2,4-dinitrotoluen instead of o-fluoronitrobenzene.
1H-NMR (D6-DMSO) in ppm: δ 10.35 (1 H,s); 8.75 (1 H,t); 8.46 (1 H,s); 8.42 (1 H,d); 7.37 (1 H,d); 8.33 (1 H,d); 8.1 (1 H,d); 7.82 (1 H,t); 7.66-7.2 (3H,m); 7.08-7.13 (3H,m).
4-r4-Benzoylamino-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 87) was prepared according the method described above using N-(4-fluoro-3-nitrophenyl)- benzylamide instead of o-fiuoronitrobenzene.
1H-NMR (D6-DMSO) in ppm: δ 10.42 (1 H,s); 10.38 (1 H,s); 8.5 (1 H,s); 8.37 (1 H,d.d.); 8.18 (1H,d); 8.15 (1 H,d); 7.96 (2H,d); 7.73 (2H,t); 7.67 (1 H,d); 7.5-7.62 (3H,m); 7.2 (1 H,d); 7.02- 7.1 (2H,m).
4-r4-Bromo-2-(3-nitrobenzoylamino)phenoxylphthalic acid (compound 88) was prepared according the method described above using 4-bromo-2-fluoro-1-nitrobenzen instead of o-fluoronitrobenzene. H-NMR (D6-DMSO) in ppm: δ 10.46 (1 H,s); 8.56 (1 H,s); 8.4 (1 H,d.d.); 8.17 (1 H,d); 7.96 (1 H,d); 7.76 (1 H,t); 7.72 (1 H,d); 7.51 (1 H,d.d.); 7.1-7.18 (3H,m). 4-f5-Fluoro-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 89) was prepared according the method described above using 2,4-difluoro-1-nitrobenzen instead of o-fluoronitrobenzene. LC-MS: m/e 463 (M+Na), 441 (MH+), 423 (MH+ - H20). 1H-NMR (D6-DMSO) in ppm: δ 10.33 (1 H,s); 8.48 (1 H,s); 8.34 (1 H,d); 8.11 (1 H,d); 7.59-7.74 (3H,m); 7.15 (1 H,d.t.); 7.05-7.1 (3H,m).
4-r4-Acetylamino-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 90) was prepared according the method described above using N-(4-fluoro-3-nitrophenyl)- acetamide instead of o-fluoronitrobenzene. LC-MS: m/e 480 (MH+), 462 (MH+ - H20).
1H-NMR (De-DMSO) in ppm: δ 10.31 (1 H,s); 10.12 (1 H,s); 8.4 (1H,s); 8.31 (1 H,d); 8.05 (1H,d); 7.89 (1H,s); 7.67 (1 H,t); 7.62 (1H,d); 7.44 (1H,d); 7.1 (1H,d); 6.99 (1H,d.d.); 6.95 (1 H,s).
4-r4-Methoxycarbonyl-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 91 ) was prepared according the method described above using methyl 4-fiuoro-3-nitrobenzoate instead of o-fluoronitrobenzene. LC-MS: m/e 481 (MH+), 463 (MH+ - H20).
1H-NMR (De-DMSO) in ppm: δ 10.50 (1 H,s); 8.63 (1H,s); 8.42 (1 H,d); 8.35 (1H,s); 8.24 (1 H,d); 7.90 (1 H,d.d.); 7.72-7.82 (2H,m); 7.18-7.26 (3H,m). 4-f4-(4-|odobenzoylamino)-2-(3-nitrobenzoylamino)phenoxylphthalic acid (Compound 92) was prepared according the method described above using N-(4-fluoro-3-nitrophenyl)-4-iodo- benzamide instead of o-fluoronitrobenzene.
LC-MS: m/e 690 (M+Na), 668 (MH+), 650 (MH+ - H20).
1H-NMR (De-DMSO) in ppm: δ 10.47 (1 H,s); 10.39 (1 H,s); 8.56 (1 H,s); 8.39 (1 H,d); 8.15-8.21 (2H,m); 7.94 (2H,d); 7.68-7.8 (5H,mt); 7.22 (1 H,d); 7.06-7.11 (2H,m).
Example 2
4-f2-(3-Aminobenzoylamino)phenoxylphthalic acid (Compound 93)
100% acetic acid (250 μl) and palladium on activated charcoal (10% Pd, 40 mg) was added to a solution of 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid (130 mg, 0.308 mmol) in methanol/water (10:1 ) (11 ml). The mixture was hydrogenated in a Parr apparatus at 276 kPa (40 psi) for 20 hours. The mixture was filtered and evaporated to dryness in vacuo to give 4-[2-(3-aminobenzoylamino)phenoxy]phthalic acid as an oil (yield: 114 mg (95%)). LC-MS: m/e 393 (MH+), 375 (MH+ - H2O). Example 3
4-(2-Aminophenoxy)phthalonitrile
A mixture of 3-nitrophthalonitrile (0.6 g, 5.78 mmol), 2-aminophenol (1 g, 5.78 mmol) and potassium carbonate (1.6 g, 11.6 mmol) in DMF (25 ml) was stirred at room temperature for 2 hours. The mixture was then purred out into water. The precipitate was filtered of, washed with water and dried to give yellow crystals of 4-(2-aminophenoxy)phthalonitrile (yield: 1.32 g (97%)). Mp: 118-118.2°C.
In a similar way the following compounds were prepared: 4-(3-Aminophenoxy)phthalonitrile from 3-nitrophthalonitrile (0.6 g, 5.78 mmol) and 3-aminophenol (1.0 g, 5.78 mmol). The product was recrystallised from methylene chloride/ hexane to give 1.27 g (93%) of beige crystals.
Mp: 171.2-172°C. 3-(2-Aminophenoxy)phthalonitrile from 2-nitrophthalonitrile (0.6 g, 5.78 mmol) and 2-aminophenol (1 ,0 g, 5.78 mmol). Evaporation in vacuo gave 1.16 g (85%) of beige crystals. Mp: 131.7-132°C.
4-(2-Nitrophenoχy)phthalonitrile from 3-nitrophthalonitrile (2.0 g, 11.5 mmol) and 2-nitrophenol (1.6 g, 11.5 mmol). The crude product was recrystallised from acetone/pentane to give 1.25 g (41%) of white crystals. Mp: 126.8-127.2°C.
Example 4
4-(2-Aminophenylsulfenyl)phthalic acid dimethyl ester Sodium hydride, 60% dispersion in mineral oil, (0.18 g, 4.5 mmol) was added to a solution of 2-aminothiophenol (0.59 ml, 4.0 mmol) in dry DMF (5 ml) at -20°C. The mixture was stirred at -20 to -30°C for 10 minutes. A solution of 4-nitrophthalic acid dimethyl ester (0.83 g, 3.5 mmol) in dry DMF (5 ml) was added dropwise. The reaction mixture was stirred at -30°C ± 5°C for 1 hour and then at room temperature for 20 hours, poured into icewater (20 ml) and finally extracted with ethyl acetate (3x25 ml). The combined organic phase was washed with water (25 ml), dried over magnesium sulphate, and evaporated to dryness in vacuo. The crude product was purified on silica gel (eluent: methylene chloride) to give 4-(2- aminophenylsulfenyl)phthalic acid dimethyl ester (yield: 0.56 g (51 %)) as a golden oil. 1H-NMR (CDCI3) in ppm: δ 3.85 (3H,s); 3.87 (3H,s); 4.29 (2H, broad s); 6.72-6.85 (2H,m); 7.07 (1 H,d.d.); 7.23-7.34 (2H,m); 7.43 (1 H,d.d.); 7.63 (1 H,d). In a similar way the following compound was prepared:
4-rBenzyl-(2-nitrophenyl)aminolphthalic acid dimethyl ester from 4-benzylaminophthaiic acid dimethyl ester (0.8 g, 2.67 mmol) and o-fluoronitrobenzene (0.34 ml, 3.2 mmol). The crude product was purified on silica gel (eluent: methylene chloride) to give 4-[benzyl-(2-nitrophenyl)amino]phthalic acid dimethyl ester as an oil (yield: 0.57 g (51%)).
1H-NMR (CDCI3) in ppm: δ 3.74 (3H,s); 3.76 (3H,s); 4.75 (2H,s); 6.52-6.65 (2H,m); 7.15-7.26 (5H,m); 7.30-7.45 (2H,m); 7.53 (1H,d.d.); 7.60 (1 H,d); 7.91 (1 H,d).
Example 5
5-(2-Aminophenoxy)isoindole-1 ,3-dione
4-(2-Aminophenoxy)phthalonitrile (1.55 g, 6.6 mmol) was stirred with cone, sulphuric acid (9 ml) at room temperature for 15 hours. The mixture was purred into crushed ice and the pH was adjusted to 10 with diluted sodium hydrogencarbonate in water. The mixture was left for the weekend at room temperature. The resulting precipitate was filtered off and washed twice with water (2x50 ml). The crystals were dried to give yellow crystals of 5-(2- aminophenoxy)isoindole-1 ,3-dione (yield: 1.41 g (84%)).
Mp: 211.6-211.9°C. In a similar way the following compound was synthesized:
5-(2-Nitrophenoxy)isoindole-1.3-dione from 4-(2-nitrophenoxy)phthalonitrile (yield: 56% white crystals).
LC/MS: m/e 285 (MH+).
Example 6 4-(2-Aminophenoxy)phthalamide
5-(2-Aminophenoxy)-isoindole-1 ,3-dione (0.1 g, 0.38 mmol) in cone, ammonium hydroxide (aq) was stirred at 60°C for two hours. The reaction mixture was evaporated in vacuo (cold in order not to make the imide again). The crude mixture was used without any purification. Example 7
N-r2-(3,4-Dicvanophenoxy)phenyllacetamide (Compound 94)
4-(2-Aminophenoxy)phthalonitrile (0.54 g, 2.3 mmol) was stirred in acetic acid anhydride (20 ml) at room temperature for 1 hour. The reaction mixture was purred into crushed ice. The precipitate was filtered off and washed with water and dried in vacuo to give N-[2-(3,4-dicyanophenoxy)phenyl]acetamide as white crystals (yield: 0.57 g (89%)). Mp: 152.2-153.7°C.
Example 8
2-r3-Cvano-4-(1 H-tetrazol-5-yl)phenoxylaniline or 2-r4-cvano-3-(1 H-tetrazol-5- vDphenoxylaniline
Ammonium chloride (0.46 g, 8.5 mmol) and sodium azide (0.55 g, 8.5 mmol) were added to a solution of 4-(2-aminophenoxy)phthalonitrile (0.5 g, 2.1 mmol) in DMF (20 ml).
The reaction mixture was heated at 80°C for 48 hours, cooled to room temperature and evaporated to dryness in vacuo. The crude compound was purified on silica gel (eluent: methylene chloride:methanol (4: 1 )) to give 2-[3-cyano-4-(1 H-tetrazol-5-yl)phenoxy]aniline or
2-[4-cyano-3-(1 H-tetrazol-5-yl)phenoxy]aniline as yellow crystals (yield: 0.64 g (95%)).
1H-NMR (CD3OD) in ppm: δ 5.2 (2H,s), 6.6 (1 H, d,d), 6.85 (1 H,d,d), 6.95 (1 H,d,d.), 7.0
(1H,d,d.), 7,45 (1H,d), 7.65 (1H,d).
13C-NMR (CD3OD) in ppm: δ 105.3; 118.7; 119.4; 119.7; 120.7; 123.0; 128.3; 133.3; 138.3; 138.3; 140.7; 142.8; 158.9; 163.4.
In a similar way the following compound was prepared:
N-{2-r3-Cyano-4-(1-H-tetrazol-5-yl)phenoxylphenyl)acetamide or N-(2-r4-cyano-3-(1-H- tetrazol-5-yl)phenoxylphenyl)acetamide (Compound 95) from N-[2-(3,4-dicyanophenoxy)phenyl]acetamide (0.55 g, 2.0 mmol), ammonium chloride (0.42 g, 8.0 mmol) and sodium azide (0.52 g, 8.0 mmol). The product was purified on silica gel (eluent: methylene chloride:methanol (4:1)) to give 0.55 g of a yellow foam.
1H-NMR (CD3OD) in ppm: δ 2.0 (3H,s), 7.1 (1H,d), 7.15 (1 H,d), 7.2-7.3 (2H,m), 7.07 (1H,d),
7.9 (1 H,d), 8.0 (1 H,s).
13C-NMR (CD3OD) in ppm: δ 23.8; 106.1 ; 119.1 ; 119.3; 119.9; 122.7; 127.3; 127.4; 128.1 ; 131.9; 134.2; 138.2; 159.3; 165.3; 166.6; 172.6. Example 9
4-Hvdroxyphthalic acid dimethyl ester
Thionyl chloride (30 ml, 0.413 mmol) is added dropvise at -10°C to a solution of 4- hydroxyphthalic acid (15 g, 82.4 mmol) in methanol (150 ml). The resulting mixture is heated at reflux temperature for 3 hours, cooled to room temperature and evaporated to dryness in vacuo to give 4-hydroxyphthalic acid dimethyl ester (yield: 17.1 g (99%)) as white crystals. 1H-NMR (CDCI3) in ppm: δ 3.86 (3H,s), 3.92 (3H,s), 6.92 (1 H,d.d.), 7.0 (1 H,d), 7.76 (1 H,d).
In a similar way the following compounds were prepared:
3-Hydroxyphthalic acid dimethyl ester from 3-hydroxyphthalic acid.
1H-NMR (CDCI3) in ppm: δ 3.88 (3H,s); 3.92 (3H,s); 6.97 (1 H,d.d.); 7.08 (1 H,d.d.); 7.47 (1 H,d.d.).
4-Nitrophthalic acid dimethylester from 4-nitrophthalic acid. 1H-NMR (CDCI3) in ppm: δ 3.98 (6H,2xs); 7.85 (1 H,d.d.); 8.41 (1 H,d.d.); 8.53 (1 H,d.d.). Mp: 63.5-66°C.
4-Hvdroxyisophthalic acid dimethyl ester from 4-hydroxyisophthalic acid.
1H-NMR (CDCI3) in ppm: δ 3.92 (3H,s); 4.0 (3H,s); 7.04 (1 H,d); 8.13 (1 H,d.d.); 8.57 (1 H,d). 4-(4-Nitrophenoxy)phthalic acid dimethyl ester from 4-(4-nitrophenoxy)phthalic acid.
1H-NMR (CDCI3) in ppm: δ 3.94 (6H, 2xs); 7.1 (2H,d); 7.22 (1 H,d.d.); 7.35 (1 H,d); 7.87 (1H,d); 8.27 (2H,d).
4-Methylphthalic acid dimethyl ester from 4-methylphthalic acid.
1H-NMR (CDCI3) in ppm: δ 2.4 (3H,s); 3.87 (3H,s); 3.90 (3H,s); 7.30 (1 H,d); 7.46 (1 H,s); 7.67 (1 H,d).
Example 10
4-Aminophthalic acid dimethyl ester Palladium on activated charcoal (10% Pd, 200 mg) was added to a solution of 4- nitrophthalic acid dimethyl ester (2.0 g, 8.37 mmol) in methylene chloride (100 ml). The mixture was hydrogenated in a Parr apparatus at 207 kPa (30 psi) for VΛ hour. The mixture was filtered and evaporated to dryness in vacuo to give 4-aminophthalic acid dimethyl ester as white crystals (yield: 1.75 g (100%)).
Mp: 83 - 85°C.
1H-NMR (CDCI3) in ppm: δ 3.80 (3H,s); 3.87 (3H,s); 6.6-6.7 (2H,m); 7.68 (1 H,d).
Example 11 4-Benzylaminophthalic acid dimethyl ester
Benzaldehyde (1.64 ml, 16.2 mmol) and sodium cyanoborohydride (1.02 g, 16.2 mmol) were added to a solution of 4-aminophthalic acid dimethyl ester (1.7 g, 8.1 mmol) in dry methanol (50 ml) and pH was adjusted to 5.5 - 6 with 2 M hydrogen chloride in methanol (approx. 1 ml). The reaction mixture was stirred at room temperature for 20 hours and evaporated to dryness in vacuo. The residue was partitioned between methylene chloride (50 ml) and water (30 ml). pH was adjusted to 8 and the organic phase was isolated, dried over magnesium sulphate and evaporated to dryness in vacuo. The crude product was purified on silica gel (eluent: ether:heptan (1 :1 )) to give 4-benzylaminophthalic acid dimethyl ester as a golden oil (yield: 0.94 g, 39%). 1H-NMR (CDCI3) in ppm: δ 3.82 (3H,s); 3.88 (3H,s); 4.35 (2H,d);4.66 (1 H, broad d); 6.57 (1H,d.d.); 6.65 (1 H,d); 7.23-7.35 (5H,m); 7.73 (1 H,d).
Example 12
4-(2-Nitrophenoxy)phthalic acid dimethyl ester
A mixture of 4-hydroxyphthalic acid dimethyl ester (1.25 g, 5.95 mmol), o-fluoronitro- benzene (0.81 ml, 7.64 mmol), and potassium carbonate (1.66 g, 12 mmol) in dry DMF (25 ml) was heated at 100°C for 1 hour. The mixture was cooled to room temperature, filtered and the filtrate evaporated to dryness in vacuo to give 4-(2-nitrophenoxy)phthalic acid dimethyl ester as a yellow oil (yield: 1.97 g (100%)).
1H-NMR (CDCI3) in ppm: δ 3.9 (6H, 2xs); 7.1-7.2 (2H,m); 7.2 (1H,d); 7.3-7.4 (1H,m); 7.6-7.7 (1 H,m); 7.84 (1 H,d); 8.03 (1 H, d.d.).
In a similar way the following compounds were prepared:
5-(2-Nitrophenoxy)isophthalic acid dimethyl ester from 5-hydroxyisophthalic acid dimethyl ester and o-fluoronitrobenzene. 1H-NMR (CDCI3) in ppm: δ 3.95 (6H, s); 7.1 (2H,d.d.); 7.3-7.4 (1 H,m); 7.55-7.65 (1 H,m); 7.87 (2H,d); 8.03 (1 H,d.d.); 8.5 (1 H, d.d.). 4-(2-Nitrophenoxy)isophthalic acid dimethyl ester from 4-hydroxyisophthalic acid dimethyl ester and o-fluoronitrobenzene.
1H-NMR (CDCI3) in ppm: δ 3.85 (3H,s); 3.95 (3H, s); 6.95-7.05 (2H,m); 7.25-7.35 (1 H,m); 7.5-
7.6 (1 H,m); 8.03 (1 H,d.d.); 8.17 (1 H,d.d.); 8.65 (1 H, d). 3-(2-Nitrophenoxy)phthalic acid dimethyl ester from 3-hydroxyphthalic acid dimethyl ester and o-fluoronitrobenzene.
1H-NMR (CDCI3) in ppm: δ 3.92 (3H,s); 3.96 (3H, s); 7.03 (1 H,d.d.); 7.17 (1 H,d.d.); 7.2-7.3
(1 H,m); 7.4-7.6 (2H,m); 7.85 (1 H,d.d.); 7.93 (1 H,d.d.).
4-(2,4-Dinitrophenoxy)phthalic acid dimethyl ester from 4-hydroxyphthaiic acid dimethyl ester (8.0 g) and 1-fluoro-2,4-dinitrobenzene (7.65 g). LC/MS: 345 (M+Na), 377 (MH+).
Example 13
4-(2-Aminophenoχy)phthalic acid dimethyl ester
A mixture of 4-(2-nitrophenoxy)phthalic acid dimethyl ester (2.16 g, 6.53 mmol) and palladium on activated charcoal (10% Pd, 120 mg) in methylene chloride (115 ml) was hydrogenated in a Parr apparatus at 207 kPa (30 psi) for 16 hours. The mixture was filtered and evaporated to dryness in vacuo to give 4-(2-aminophenoxy)phthalic acid dimethyl ester as an yellow oil (yield: 1.88 g (96%)).
1H-NMR (CDCI3) in ppm: δ 3.86 (3H,s); 3.90 (3H, s); 6.7-6.97 (3H,m); 7.0-7.1 (2H,m); 7.15 (1H,d); 7.78 (1 H,d).
13C-NMR (CDCI3) in ppm: δ 52.9; 53.2; 116.5; 117.4; 118.2; 119.4; 121.6; 124.4; 126.7;
132.1 ; 136.1 ; 139.2; 141.6; 160.8; 167.1 ; 168.8.
In a similar way the following compounds were prepared:
5-(2-Aminophenoxy)isophthalic acid dimethyl ester from 5-(2-nitrophenoxy)-isophthalic acid dimethyl ester. H-NMR (in CDCI3): 3.95 (6H, s); 6.7-6.8 (1 H,m); 6.8-6.9 (2H,m); 7.0-7.1 (1 H,m); 7.8 (2H,d); 8.37 (1 H,t).
4-(2-Aminophenoxy)isophthalic acid dimethyl ester from 4-(2-nitrophenoxy)-isophthalic acid dimethyl ester. 1H-NMR (CDCI3) in ppm: δ 3.91 (3H,s); 3.94 (3H, s); 6.7-7.1 (5H,m); 8.03 (1 H.d.d.); 8.53 (1 H,d). 3-(2-Aminophenoxy)phthalic acid dimethyl ester from 3-(2-nitrophenoxy)phthalic acid dimethyl ester.
1H-NMR (CDCI3) in ppm: δ 3.90 (3H,s); 3.97 (3H,s); 4.0-4.7 (NH2,broad) ; 6.65-6.72 (2H,m);
6.94-7.08 (3H,m);7.32 (1 H,dd); 7.69 (1 H,dd). 4-(4-Aminophenoxy)phthalic acid dimethyl ester from 4-(4-nitrophenoxy)phthalic acid dimethyl ester.
1H-NMR (CDCI3) in ppm: δ 3.90 (3H,s); 3.92 (3H, s); 6.7 (2H,d); 6.9 (2H,d); 7.02 (1H,d.d.); 7.07 (1 H,d); 7.78 (1 H,d).
4-(2,4-Diaminophenoxy)phthalic acid dimethyl ester from 4-(2,4-dinitrophenoxy)phthalic acid dimethyl ester. LC/MS: m/e 339 (M+Na), 317 (MH+), 285.
Example 14
4-r(2-Aminophenyl)benzylaminolphthalic acid dimethyl ester
A clear solution of stanno chloride dihydrate (0.84 g, 3.72 mmol) in DMF (4 ml) was added to a solution of 4-[benzyl-(2-nitrophenyl)amino]phthalic acid dimethyl ester (195 mg, 0.47 mmol) in DMF (4 ml) and stirred for 3 hours at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate (2x25 ml). The collected organic phases was washed with water (3x25 ml), dried over magnesium sulphate, and evaporated to dryness in vacuo to give 4-[(2-aminophenyl)benzylamino]phthalic acid dimethyl ester as a slightly coloured oil (yield: 180 mg (100%)).
Example 15
4-r2-(3-Nitrobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 96)
A solution of 3-nitrobenzoyl chloride (0.43 g, 2.3 mmol) in dry acetone (2 ml) was added slowly to a solution of 4-(2-aminophenoxy)phthalic acid dimethyl ester (0.63 g, 2.09 mmol) and TEA (0.35 ml, 2.5 mmol) in dry acetone (2 ml) at 0°C. The mixture was stirred at room temperature for 20 hours, filtered and the filtrate evaporated to dryness in vacuo. The crude product was purified on silica gel (eluent: methylene chloride/ethyl acetate (95:5)) to give 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester (yield: 1.19 g (47%)) as a golden oil. 1H-NMR (CDCI3) in ppm: δ 3.9 (6H,2xs); 7.02 (1 H,d.d.); 7.1-7.25 (2H,m); 7.25-7.35 (2H,m);
7.7 (1 H,t); 7.83 (1 H,d); 8.1 (1 H,d.t.); 8.3 (1 H, broad s); 8.4 (1 H,m); 8.54 (1 H,d.d); 8.65 (1 H,m). In a similar way the following compounds were prepared: 5-r2-(3-Nitrobenzoylamino)phenoxylisophthalic acid dimethyl ester (Compound 97) from 5-(2-aminophenoxy)isophthalic acid dimethyl ester and 3-nitrobenzoyl chloride. 1H-NMR (CDCI3) in ppm: δ 3.96 (6H,s); 6.9 (1 H,d.d.); 7.15 (2H,d.t.); 7.25 (1 H,d.t.); 7.68 (1 H,t); 7.92 (1 H,d); 8.16 (1 H,d.t.); 8.35-8.41 (1 H,m); 8.43 (1 H,broad s); 8.5 (1 H,m); 8.57 (1H,d.d.); 8.63 (1 H,t).
4-r2-(3-Nitrobenzoylamino)phenoxylisophthalic acid dimethyl ester (Compound 98) from 4-(2-aminophenoxy)isophthalic acid dimethyl ester and 3-nitrobenzoyl chloride. 1H-NMR (CDCI3) in ppm: δ 3.9 (3H,s); 3.94 (3H,s); 7.1 (1 H,d.); 7.2 (2H,m); 7.3-7.5 (1 H,m); 7.64 (1 H,t); 8.1 (1 H,d.d.); 8.25-8.4 (2H,m); 8.55 (1 H,d); 8.63 (1 H,d); 8.7 (1 H,m). 4-r4-(3-Nitrobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 99) from 4-(4-aminophenoxy)phthalic acid dimethyl ester and 3-nitrobenzoyl chloride. 1H-NMR (CDCI3) in ppm: δ 3.88 (6H,2xs); 7.0-7.2 (4H,m); 7.65-7.75 (3H,m); 7.8 (1 H,d); 8.3 (1H,d.t.); 8.4 (1 H,d.m.); 8.5 (1 H,broad s); 8.75 (1 H,m).
3-f2-(3-Nitrobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 100) from 3-(2-aminophenoxy)phthalic acid dimethyl ester and 3-nitrobenzoyl chloride. H-NMR (CDCI3) in ppm: δ 3.90 (6H,2xs) ; 6.95 -7.45 (5H,m); 7.55 - 7.75 (2H,m); 8.15 (1 H,d.d.); 8.39 (1 H,d.d.); 8.48 (1 H,d.d.); 8.65 (1 H,d.d.); 8.85 (1 H,broad s). SP/MS: M+: 450.
4-r2-(3-Nitrobenzoylamino)phenylsulphenyllphthalic acid dimethyl ester (Compound 101 ) from 4-(4-aminophenylsulphenyl)phthalic acid dimethyl ester and 3-nitrobenzoyl chloride. 1H-NMR (CDCI3) in ppm: δ 3.85 (3H,s); 3.9 (3H,s); 7.15 (1 H,d.d.); 7.3 (1 H,m.t.); 7.4 (1 H,d); 7.5-7.7 (4H,m); 8.0 (1 H,d.m.); 8.36 (1 H, d.m.); 8.53 (1 H,t); 8.6 (1 H,d.d.); 9.0 (1 H, broad s).
4-(Benzyl-r2-(3-nitrobenzoylamino)phenyllamino)phthalic acid dimethyl ester (Compound 102) from 3-nitrobenzoyl chloride and 4-[(2-aminophenyl)benzylamino]phthalic acid dimethyl ester. LC-MS: m/e 540 (MH+), 509.
4-r2-(3-Nitrobenzoylamino)benzyllphthalic acid dimethyl ester (Compound 103) from 3-nitrobenzoyl chloride and 4-(2-aminobenzyl)phthalic acid dimethyl ester. 1H-NMR (CDCI3) in ppm: δ 3.85 (3H,s); 3.9 (3H,s); 4.14 (2H,s); 7.25-7.40 (4H,m); 7.43 (1 H,d); 7.66 (4H,p); 7.90 (1 H,d); 8.36 (1 H.d.m.); 8.40 (1 H,t). LC-MS: m/e 471 (M+Na), 449 (MH+). N-f2-(1 ,3-Dioxo-2,3-dihydro-1 H-isoindol-5-yloxy)phenyll-3-nitrobenzamide (Compound 104) from 5-(2-aminophenoxy)isoindole-1 ,3-dione (18 mg, 0.07 mmol) and 3-nitrobenzoylchloride (21 mg, 0.11 mmol). The reaction mixture was stirred at room temperature for 4 hours. The mixture was evaporated in vacuo and the residue was purified on silica gel to give N-[2-(1 ,3- dioxo-2,3-dihydro-1 H-isoindol-5-yloxy)phenyl]-3-nitrobenzamide as white crystals (yield: 9 mg (32%)). LC-MS: m/e 404 (MH+).
4-F2-(3-Tr.fluoromethylbenzoylamino)phenoxy1phthalic acid dimethyl ester (Compound 105) from 4-(2-aminophenoxy)phthalic acid dimethylester (100 mg) and 3-trifluoromethylbenzoyl chloride (68 mg) (yield: 120 mg (78%)). LC/MS : m/e 474 (MH+).
4-(2-r(2-Chlorothiophene-3-carbonyl)aminolphenoxy)phthalic acid dimethyl ester (Compound 106) from 4-(2-aminophenoxy)phthalic acid dimethylester (100 mg) and 3-chloro-2-thiophene- carboxylic acid chloride (60 mg) (yield: 105 mg (71%)). LC/MS: m/e 446 (MH+).
4-r2-(3-Trifluoromethoxybenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 107) from 4-(2-aminophenoxy)phthalic acid dimethylester (200 mg) and 3-trifluoromethoxybenzoyl chloride (137 mg). 4-r2-(3-Fluorobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 108) from 4-(2-aminophenoxy)phthalic acid dimethylester (200 mg) and 3-fluorobenzoyl chloride (126 mg) (yield: 239 mg (85%). LC/MS: m/e: 446 (M+Na), 393.
4-f2-(3-Ethoxycarbonylbenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 109) from 4-(2-aminophenoxy)phthalic acid dimethylester (0.50 g) and 3-ethoxycarbonylbenzoyl chloride (0.58 g) (yield: 0.64 g (100%).
1H-NMR (CDCI3) in ppm: δ 1.4 (3H,t); 3.9 (6H,2xs); 4.40 (2H,q); 6.98 (1 H,d.d.); 7.10-7.33 (4H,m); 7.56 (1H,t); 7.83 (1H,d); 7.97 (1H,d.m.); 8.20 (1 H,d.m.); 8.30 (1 H,broad s); 8.45 (1 H,t); 8.60 (1 H,d.d.). 4-[2-(3-Methoxycarbonylpropionylamino)phenoxylphthalic acid dimethyl ester (Compound 110) from 4-(2-aminophenoxy)phthalic acid dimethylester (100 mg) and 3-methoxycarbonyl- propanoyl chloride (41 mg) (yield: 91 mg (80%). LC/MS: m/e 438 (M+Na), 384. 4-r2-(4-Methoxycarbonylbutyrylamino)phenoxylphthalic acid dimethyl ester (Compound 111 ) from 4-(2-aminophenoxy)phthalic acid dimethylester (100 mg) and 4-methoxycarbonyl- butanoyl chloride (38 ml) (yield: 111 mg (95%)). LC/MS: m/e 452 (M+Na), 430 (MH+), 398. 4-r2-(3-Ethoxycarbonylacryloylamino)phenoxylphthalic acid dimethyl ester (Compound 112) from 4-(2-aminophenoxy)phthalic acid dimethylester (200 mg) and 3-ethoxycarbonyl- propenoyl chloride (106 mg) (yield: 85 mg (36%)). LC/MS: m/z 450 (M+Na), 396.
4-f2.4-Bis-(2-bromo-4-nitrobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 113) from 4-(2,4-diaminophenoxy)phthalic acid dimethyl ester (0.53 g) and 2-bromo-5-nitrobenzoyl chloride (1.0 g). The crude product purified on silicagel column (eluent: methylene chloride:methanol (5:1 )) to give 4-[2,4-bis-(2-bromo-4-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester as brownish crystals (yield: 0.81 g 63%). Mp:138-142°C.
LC/MS: 794 (M+Na), 773 (MH+), 740 (M-OMe).
CHN: Calculated: C: 46.66; H: 2.61; N: 7.25; Br: 20.69. Found C: 47.05; H: 2.94; N: 6.85;
Br: 20.22.
4-f4-(3-Nitrobenzoylamino)benzovπphthalic acid dimethyl ester (Compound 114) from 4-(4-aminobenzoyl)phthalic acid dimethyl ester (250 mg) and 3-nitrobenzoyl chloride (148 mg) to give yellow crystals of 4-[4-(3-nitrobenzoylamino)benzoyl]phthalic acid dimethyl ester (yield: 350 mg 100%). Mp: 144-146°C. LC/MS: m/e 485 (M+Na),463 (MH+). 4-r2-(3-Nitrobenzoylamino)benzoyllphthalic acid dimethyl ester (Compound 115) from 4-(2-aminobenzoyl)phthalic acid dimethyl ester (250 mg) and 3-nitrobenzoyl chloride (148 mg) to give 4-[2-(3-nitrobenzoylamino)benzoyl]phthalic acid dimethyl ester as yellow crystals (yield: 318 mg (85%)). Mp: 133-137°C. LC/MS: m/e 485 (M+Na), 463 (MH+), 431.
4-f2-(3-Chloromethylbenzoylamino)phenoxy1phthalic acid dimethyl ester (Compound 116) from dimethyl 4-(2-aminophenoxy)phthalate (0.10 g, 0.27 mmol) and 3-chloromethylbenzoyl chloride (51 mg, 0.27 mmol) (yield: 96 mg (80%)). LC/MS: m/e 454 (M+), 422. N-(2-r3-Cvano-4-(1 H-tetrazol-5-yl)phenoxylphenyl)-3-nitrobenzamide or N-(2-r4-cyano-3-(1 H- tetrazol-5-yl)phenoxylphenyl}-3-nitrobenzamide (Compound 117) from 5-(2-aminophenoxy)-2-(1 H-tetrazol-5-yl)benzonitrile (0.15 g, 0.47 mmol) and 3-nitrobenzoyl chloride (95 mg, 0.51 mmol) (yield: 6 mg (3%)). H-NMR (acetone-de) in ppm: δ 7.3 (m,3H); 7.6 (t,2H); 7.9 (d,1 H); 8.15 (m,1 H); 8.25 (d,1 H); 8.45 (d,1H); 8.6 (s,1 H). LC/MS: m/e 428 (M+1 ).
Example 16
4-r2-(3-Nitrobenzoylamino)benzenesulfinyllphthalic acid dimethyl ester (Compound 118) 3-Chloroperoxybenzoic acid, 70%, (32.5 mg, 0.132 mmol) was added to a solution of 4-
(2-aminophenylsulfenyl)phthalic acid dimethyl ester (60 mg, 0.129) in methylene chloride (1 ml). The mixture was stirred at room temperature for 1 hour, diluted with methylene chloride (2 ml) and with 10% aqueous sodium hydrogencarbonate (0.5 ml). The organic phase was isolated, dried over magnesium sulphate and evaporated to dryness in vacuo. The crude product was purified on silica gel (eluent: methylene chloride:ethyl acetate (90:10)) to give 4- [2-(3-nitrobenzoylamino)-benzenesulfinyl]phthalic acid dimethyl ester as a thick, colourless oil (yield: 29 mg (47%)).
1H-NMR (CDCI3) in ppm: δ 3.80 (3H,s); 3.87 (3H,s); 7.33 (1 H,d.t.); 7.55-7.80 (5H,m); 7.90 (1H,d); 8.30 (1 H,d); 8.42 (1 H, d.m.); 8.62 (1 H,d); 8.8 (1 H,t); 11.16 (1 H,s). In a similar way the following compound was prepared:
4-f2-(3-Nitrobenzoylamino)benzenesulfonyllphthalic acid dimethyl ester (Compound 119) from 4-(2-aminophenylsulfenyl)phthalic acid dimethyl ester.
1H-NMR (CDCI3) in ppm: δ 3.82 (3H,s); 3.90 (3H,s); 7.37 (1 H,d.t.); 7.67-7.85 (2H,m); 7.96 (1 H,d.d.); 8.06 (1 H,d.d.); 8.24 (1 H,d); 8.32 (1 H,d.t.); 8.47 (1 H,d.m.); 8.67 (1H,d.d.); 8.87 (1H,t); 10.8 (1 H,s).
Example 17
4-r2-(3-Nitrobenzylamino)phenoxylphthalic acid dimethyl ester (Compound 120)
A solution of 3-(2-aminophenoxy)phthalic acid dimethyl ester (200 mg, 0.54 mmol) and 3-nitrobenzaldehyde (90 mg, 0.60 mmol) in toluen (20 ml) was refluxed for 30 hours with a Dean-Stark trap. The reaction mixture is cooled to room temperature and evaporated to dryness in vacuo. The residue was dissolved in methanol (5 ml), sodium cyanoborohydride (100 mg, 1.58 mmol) was added, and pH adjusted to 4.5 by means of hydrogen chloride in ether. The mixture was stirred at room temperature for 20 hours, evaporated to dryness in vacuo, and partioned between methylene chloride (5 ml) and water (5 ml). The organic phase was isolated, dried over magnesium sulphate, and evaporated to dryness in vacuo. The crude compound was purified on silica gel (eluent: methylene chloride:ethyi acetate (95:5)) to give 4-[2-(3-nitrobenzylamino)phenoxy]phthalic acid dimethyl ester as a yellow oil (yield: 130 mg (55%). 1H-NMR (CDCI3) in ppm: δ 8.05-8.18 (2H,m); 7.84 (1 H,d); 7.63 (1H,d); 7.50 (1 H,t); 7.20
(1 H,d); 6.9-7.1 (3H,m); 6.73 (1 H,d.t.); 6.6 (1 H,d.d.); 4.56 (1 H, broad s); 4.48 (2H,broad s); 3.9
(3H,s); 3.87 (3H,s).
LC-MS: m/e 459 (M+Na), 437 (MH+).
Example 18 4-r2-(tert-Butoxycarbonylamino)benzyllphthalic acid dimethyl ester
N-Bromosuccinimide (4.3 g, 24.2 mmol) and benzoylperoxide (50 mg) was added to a solution of 4-methylphthalic acid dimethyl ester in carbon tetrachloride (50 ml). The mixture was heated to reflux temperature for two hours, cooled to room temperature and evaporated to dryness in vacuo to give 4-bromomethylphthalic acid dimethyl ester. The crude product was used in the next step without purification.
A mixture of 4-bromomethylphthalic acid dimethyl ester (3.1 g, 10.8 mmol), 2-(tert- butoxycarbonylamino)phenylboronic acid (4.3 g, 18.1 mmol), tetrakis(triphenylphosphine)- palladium(O) (0.6 g), 2 M aqueous sodium carbonate (20 ml), and 1 ,2-dimethoxyethane (40 ml) was heated at 90°C for 19 hours. The reaction mixture was cooled to room temperature and partioned between water (60 ml) and methylene chloride (60 ml). The organic phase was isolated, washed with water (2x50 ml), dried over magnesium sulphate, and evaporated to dryness in vacuo. The crude product was purified on silica gel (eluent: methylene chloride:ethyl acetate (95:5) to give 4-[2-(tert-butoxycarbonylamino)benzyl]phthalic acid dimethyl ester as yellow crystals (yield: 1.49 g (40%)). 1H-NMR (CDCI3) in ppm: δ 7.70 (1 H,d); 7.67 (1 H,d); 7.47 (1 H,d); 7.22-7.33 (2H,m); 7.10 (2H,d); 6.05 (1 H,s); 4.03 (2H,s); 3.9 (6H,2xs); 1.47 (9H,s).
Example 19
4-(2-Aminobenzyl)phthalic acid dimethyl ester
2N hydrogen chloride in diethyl ether (1 ml) was added to a solution of 4-(2-(tert- butoxycarbonylamino)benzyl)phthalic acid dimethyl ester (100 mg, 0.25 mmol) in methanol (1 ml). The mixture was stirred for 2 hours at room temperature and evaporated to dryness in vacuo. The crude product was recrystaliized from diethyl ether/ethyl acetate to give light, golden crystals of 4-(2-aminobenzyl)phthalic acid dimethyl ester (yield: 69 mg (86%)). 1H-NMR (CDCI3) in ppm: δ 7.74 (1 H,d); 7.60 (1 H,s); 7.54 (1 H,d); 7.27 (2H,d); 7.13 (1 H,m); 7.05 (1 H,d); 4.12 (2H,s); 3.8 (6H,2xs); 2.5 (3H,s). LC-MS: m/e 322 (M+Na), 300 (MH+).
Example 20
4-r2-(3-Nitrobenzoylamino)phenoxylphthalic acid (Compound 1 ) 2N sodium hydroxide (12 ml) was added to a solution of 4-(2-(3-nitrobenzoylamino)- phenoxy)phthalic acid dimethylester (1.15 g, 2.83 mmol) in 1 ,4-dioxan (12 ml) at room temperature. The mixture was stirred for 2 hours, cooled to < 10°C and pH adjusted to 2-3 with 1 N hydrochloric acid (approx. 24 ml). The resulting crystals were filtered off and washed with water. The crystals were dried to give beige crystals of 4-[2-(3-nitrobenzoylamino)- phenoxyjphthalic acid (yield: 0.82 g (76%)).
1H-NMR (DMSO-de) in ppm: δ 10.3 (s, 1H), 8.58 (m, 1H), 8.38 (m, 1H), 8.18 (d, 1H), 7.6-7.8 (m, 3H), 7.3-7.4 (m, 2H), 7.18 (d.d., 1 H), 7.1 (m, 1 H), 7.07 (d.d., 1 H). Mp: 199.7-201.0°C.
In a similar way the following compounds were prepared: 5-r2-(3-Nitrobenzoylamino)phenoxylisophthalic acid (Compound 121 ) from 5-[2-(3-nitrobenzoylamino)phenoxy]isophthalic acid dimethylester. Mp: 184-190°C.
4-f2-(3-Nitrobenzoylamino)phenoxylisophthalic acid (Compound 122) from 4-[2-(3-nitrobenzoylamino)phenoxy]isophthalic acid dimethylester. Mp: 255-257°C.
4-[4-(3-Nitrobenzoylamino)phenoxylphthalic acid (Compound 123) from 4-[4-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethylester. Mp: 225-227°C.
3-[2-(3-Nitrobenzoylamino)phenoxy1phthalic acid (Compound 124) from 3-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethylester. LC-MS: m/e 423 (MH+).
4-r2-(3-Nitrobenzoylamino)phenylsulphenyr|phthalic acid (Compound 125) from 4-[2-(3-nitrobenzoylamino)phenylsulphenyl]phthalic acid dimethylester. Mp: 172.8-173.9°C. 4-r2-(3-Nitrobenzoylamino)benzenesulfinyllphthalic acid (Compound 126) from 4-[2-(3-nitrobenzoylamino)benzenesulfinyl]phthalic acid dimethylester. 1H-NMR (CD3OD) in ppm: δ 8.8 (1 H,t); 8.5 (1 H,d.m.); 8.33 (1 H,d.t.); 8.05 (1 H,s); 7.86 (3H,t); 7.6-7.30 (3H,m); 7.50 (1H,d.t.).
LC-MS: m/e 477 (M+Na), 455 (MH+), 437 (MH+ - H20).
4-r2-(3-Nitrobenzylamino)phenoxylphthalic acid (Compound 127) from 4-[2-(3-nitrobenzylamino)phenoxy]phthalic acid dimethyl ester. 1H-NMR (DMSO-d6) in ppm: δ 8.18 (1 H,s); 8.08 (1 H,d); 7.77 (2H); 7.60 (1 H,t); 7.04 (2H,s); 6.9-7.0 (2H,m); 6.57-6.67 (2H,m); 6.33 (1 H,broad s); 4.50 (1 H,s). LC-MS: m/e 431 (M+Na), 409 (MH+), 391 (MH+ - H20).
4- Benzyl-f2-(3-nitrobenzoylamino)phenvπamino)phthalic acid (Compound 128) from 4-{benzyl-[2-(3-nitrobenzoylamino)phenyl]amino}phthalic acid dimethyl ester. LC-MS: m/e 534 (M+Na), 512 (MH+), 494 (MH+ - H20).
4-r2-(3-Nitrobenzoylamino)benzyllphthalic acid (Compound 129) from 4-[2-(3-nitrobenzoylamino)benzyl]phthalic acid dimethyl ester. 1H-NMR (DMSO-d6) in ppm: δ 13.0 (2H, broad s); 10.30 (1H,s); 8.66 (1H,s); 8.41 (1H,d.d.); 8.27 (1 H,d); 7.80 (1 H,t); 7.53 (1 H,d); 7.26-7.37 (6H,m); 4.10 (2H,s). LC-MS: m/e 443 (M+Na), 421 (MH+), 403 (MH+ - H20).
4-r2-(3-Trifluoromethylbenzoylamino)phenoxylphthalic acid (Compound 130) from 4-[2-(3-trifluoromethylbenzoylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 468 (M+Na), 428 (MH+- H20).
4-{2-r(2-Chlorothiophene-3-carbonyl)aminolphenoxylphthalic acid (Compound 131) from 4-{2-[(2-chlorothiophene-3-carbonyl)amino]phenoxy}phthalic acid dimethyl ester. LC/MS: m/e 401 (MH+- H20).
4-r2-(3-Trifluoromethoxybenzoylamino)phenoxy1phthalic acid (Compound 132) from 4-[2-(3-trifluoromethoxybenzoylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 462 (MH+), 420. 4-r2-(3-Fluorobenzoylamino)phenoxylphthalic acid (Compound 133) from 4-[2-(3-fiuorobenzoylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 418 (M+Na), 378 (MH+- H20).
4-r2-(3-Carboxyphenylcarbamoyl)phenoxylphthalic acid (Compound 134) from 4-[2-(3-ethoxycarbonylbenzoylamino)phenoxy]phthalic acid dimethyl ester. Mp: 202-208°C.
LC/MS: m/e 467 (M+2Na), 404 (MH+- H20). 4-r2-(3-Carboxypropionylamino)phenoxylphthalic acid (Compound 135) from 4-[2-(3-methoxycarbonylpropionylamino)phenoxy]phthalic acid dimethyl ester.
LC/MS: m/e 396 (M+Na), 356 (MH+- H2O).
4-f2-(4-Carboxybutyrylamino)phenoxylphthalic acid (Compound 136) from 4-[2-(4-methoxycarbonylbutyrylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 410 (M+Na), 388 (MH+), 370 (MH+- H2O).
4-r2-(3-Carboxyacryloylamino)phenoxylphthalic acid (Compound 137) from 4-[2-(3-ethoxycarbonyl-2-propenoylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 394 (M+Na), 354 (MH+- H2O). 13C NMR (MeOH-d4): δ 170.4; 169.0; 167.5; 163.9; 160.2; 147.3; 136.8; 134.4; 131.9; 131.8; 130.1 ; 126.9; 126.2; 125.5; 125.2; 120.7; 118.9; 117.4.
4-r2-(3-Nitrobenzoylamino)benzovnphthalic acid (Compound 138) from 4-[2-(3-nitrobenzoylamino)-benzoyl]phthalic acid dimethyl ester. LC/MS: m/e 457 (M+Na), 417 (MH+- H2O). 4-r4-(3-Nitrobenzoylamino)benzovHphthalic acid (Compound 139) from 4-[4-(3-nitrobenzoylamino)benzoyl]phthalic acid dimethyl ester. LC/MS: m/e 457 (M+Na), 435 (MH+), 417 (MH+- H20).
4-r2,4-Bis-(2-bromo-5-nitrobenzoylamino)phenoxylphthalic acid (Compound 140) from 4-[2,4-bis-(2-bromo-4-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 764/762/760 (M+NH4 +), 729/727/725 (MH+-H20).
CHN: Calculated: C: 45.19; H: 2.17; N: 7.53; Br: 21.47. Found C: 44.52; H: 2.81 ; N: 6.96; Br:
20.43 (in accordance with the monohydrate).
13C NMR (MeOH-d4): δ 171.3; 170.1 ; 167.2; 167.0; 161.9; 148.9; 148.7; 145.3; 141.4; 141.0;
138.2; 137.2; 136.2; 136.1 ; 133.3; 131.5; 128.4; 128.3; 127.1 ; 125.1 ; 123.2; 120.7; 119.7; 119.1 ; 118.0.
4-r2-(3-Chloromethylbenzoylamino)phenoxylphthalic acid (Compound 141 ) from 4-[2-(3-chloromethylbenzoylamino)phenoxy]phthalic acid dimethyl ester. LC/MS: m/e 390 (M-HCI), 372 (M-HCI-H20).
Example 21 4'-lodo-2-nitrodiphenyl ether
4-lodophenol (1 g, 4.5 mmol) was dissolved in DMF (20 ml). 2-Fluoronitrobenzene (0.64 g, 4.5 mmol) and K2C03 were added. The reaction mixture was refluxed at 160°C for 4 hours. The reaction mixture was poured into ice and stirred for 1 hour. The precipitate was filtered off, washed with water, and dried in vacuo to give 4'-iodo-2-nitrodiphenyl ether as slightly beige crystals (yield: 1.31 g (85%)). Mp: 88.8-90.8°C.
In a similar way the following compound was synthesized: 3-lodo-2'-nitrodiphenyl ether
3-lodophenole (3.0 g, 13.6 mmol) was dissolved in DMF (20 ml) and 2-fluoronitro- benzene (1.92 g, 13.6 mmol) and K2C03 (2.07 g, 15 mmol) were added. The reaction mixture was heated to 160°C for 15 hours. The mixture was poured into ice and was stirred for 1 hour. The resulting oil was extracted with methylene chloride (4x100 ml). The organic phase was dried over magnesium sulphate and evaporated in vacuo (yield: 4.45 g (96%) yellow oil). 1H-NMR (CDCI3) in ppm: δ 6.85-7.1 (m,3H); 7.25 (t.d.,1 H); 7.4 (m,1 H); 7.55 (m,1 H); 7.95 (d.d.,1 H).
Example 22
[4-(2-Nitrophenoxy)phenyllphosphonic acid diethyl ester 4'-lodo-2-nitrodiphenyl ether (0.3 g, 0.88 mmol) was melted at 150°C under N2, and phosphorous acid triethyl ester (0.175 g, 1.06 mmol) and NiCI2 (6 mg, 0.044 mmol) were added. The mixture was stirred at 150°C under N2 for 3 hours. The mixture was cooled and water/methylene chloride was added. The water phase was extracted with methylene chloride (2x50 ml). The organic phase was dried with magnesium sulphate, filtered and evaporated in vacuo. The remaining brown oil was purified on a silica gel column (eluent: methylene chloride/methanol (39:1 )) to give the title compound as a yellow oil (yield: 0.14 g
(45%)).
1H-NMR (CDCI3) in ppm: 1.3 (6H, t); 4.15 (4H, q); 7.05 (1 H, d); 7.08 (1H, d); 7.15 (1H, dd);
7.35 (1 H, d.t.); 7.62 (1 H, d.t.); 7.8 (1 H, d); 7.85 (1 H, d); 7.95 (1 H, d.d.). 13C-NMR (CDCI3) in ppm: 16.6; 16.8; 62,5; 62,6; 117.9; 118.3; 122.0; 122.9; 125.3; 125.9;
126.3; 134,3; 134,5; 135.0; 142,4; 149,1 ; 160,3; 160,4.
In a similar way the following compound was synthesized: r3-(2-Nitrophenoxy)phenvπphosphonic acid diethyl ester
3-lodo-2'-nitrodiphenylether (4.45 g, 13 mmol) was heated to 150°C under N2, and phosphorous acid triethyl ester (4.33 g, 26.1 mmol) and NiCI2 were added. The mixture was heated 2 hours to 150°C under N2. Further phosphorous acid triethyl ester (4.33 g, 26.1 mmol) and NiCI2 were added and the reaction mixture was heated for 15 hours. After cooling to room temperature water and methylene chloride were added. The water phase was extracted with methylene chloride (2x50 ml). The organic phase was dried over magnesium sulphate and evaporated in vacuo. The residue was purified on a silica gel column (eluent: methylene chloride/methanol (39:1 )) (yield: 2.28 g yellow oil (50%)).
1H-NMR (CDCI3) in ppm: δ 1.3 (t,6H); 4.1 (q,4H); 7.05 (d.d.,1 H); 7.3 (m,3H); 7.4-7.7 (m,3H);
8.0 (d.d.,1 H).
Example 23 r4-(2-Aminophenoxy)phenyllphosphonic acid diethyl ester
[4-(2-Nitrophenoxy)phenyl]phosphonic acid diethyl ester (140 mg, 0.4 mmol) was dissolved in methylene chloride and Pd/C 10% was added under N2. The compound was reduced with H2 in a Parr-apparatus at 207 kPa (30 psi) for 15 hours. The catalyst was filtered off and the organic phase was evaporated in vacuo. The remaining oil was purified on a silica gel column (eluent: methylene chloride/methanol (39:1 )) to give the title compound as an oil (yield: 118 mg (92%)). H-NMR (CDCI3) in ppm: 1.32 (6H, t); 3.8 (2H,broad s); 4.1 (4H,q); 6.7 (1 H,d.t.); 6.85
(1H,d.d.); 6.9 (1H,d.d.); 7.0 (3H,m); 7.7 (1H, d); 7.85 (1H,d). 13C-NMR (CDCI3) in ppm: 16.7; 16.8; 62,4; 62,5; 116.5; 116.8; 117.2; 119.2; 119.9; 121.7;
123.8; 126.4; 134.2; 134.4; 139.5; 141.8; 161.6; 161.6.
In a similar way the following compound was synthesized: f3-(2-Aminophenoxy)phenyllphosphonic acid diethyl ester from [3-(2-nitrophenoxy)phenyl]phosphonic acid diethyl ester (2.28 g, 6.5 mmol) (yield: 0.77 g (37%) yellow oil).
1H-NMR (CDCI3) in ppm: δ 1.25 (t.d.,6H); 3.9 (broad s,2H); 4.1 (m,4H); 6.65 (t.d.,1 H); 6.8 (t.d.,2H); 6.95 (t.d.,1 H); 7.1 (d.d.,1 H); 7.3-7.55 (m,3H).
Example 24
(4-r2-(3-Nitrobenzoylamino)phenoxylphenyl)phosphonic acid diethyl ester (Compound 142) [4-(2-Aminophenoxy)phenyl]phosphonic acid diethyl ester (118 mg, 0.37 mmol) was dissolved in acetone (20 ml) and 3-nitrobenzoylchloride (7.5 mg, 0.40 mmol) and TEA (9.3 mg, 0.92 mmol) were added. The reaction mixture was stirred at room temperature for 72 hours. The reaction mixture was evaporated in vacuo and the residue was dissolved in methylene chloride/water (2x30 ml). The organic phase was dried over magnesium sulphate, filtered and evaporated in vacuo. The remaining yellow oil was purified on a silica gel column (eluent: methylene chloride/methanol (19:1 )) to give the title compound as an oil (yield: 8.7 mg (50%)).
1H-NMR (CDCI3 in ppm): 1.3 (6H, t); 4.05 (4H,q); 7 (1 H,d.d.); 7.15 (2H,d.d.); 7.25 (2H,m); 7.6-7.85 (3H,m); 8.1 (1 H, d.d.); 8.35 (1 H,d.d.); 8.45 (1 H,d.d.); 8.6 (2H,m). 13C-NMR (CDCI3 in ppm): 16.6; 16.8; 62,5; 62,6; 117.9; 118.2; 1 19.7; 122.0; 122.6; 122.8; 125.4; 125.7; 125.8; 126.8; 129.6; 130.0; 130.4; 133.4; 134.4; 134.6; 136.7; 145.7; 148.7; 160.3; 160.4; 163.5.
In a similar way the following compound was synthesized: 3-r2-(3-Nitrobenzoylamino)phenoxylphenyl)phosphonic acid diethyl ester (Compound 143) from [3-(2-aminophenoxy)phenyl]phosphonic acid diethyl ester (0.10 g, 0.31 mmol) and 3- nitrobenzoylchloride (69 mg, 0.37 mmol) (yield: 110 mg oil (75%)). 1H-NMR (CDCI3) in ppm: δ 1.3 (t,6H); 4.1 (m,4H); 6.9 (d.d.,1 H); 7.1-7.3 (m,3H); 7.45-7.8 (m,3H); 8.15 (d.t.,1 H); 8.35 (d.d.,1 H); 8.45 (d.d.,1 H); 8.7 (m,2H).
Example 25
(4-r2-(3-Nitrobenzoylamino)phenoxy1phenyl)phosphonic acid (Compound 144)
{4-[2-(3-Nitrobenzoylamino)phenoxy]phenyl}phosphonic acid diethyl ester (5 mg, 0.11 mmol) was dissolved in methylene chloride (5 ml) and trimethylsilylbromide (13 mg, 0.85 mmol) was added. The reaction mixture was stirred for 16 hours at room temperature. Water (5 ml) was added and the mixture was stirred vigorously until precipitation of white crystals of
{4-[2-(3-nitrobenzoylamino)phenoxy]phenyl}phosphonic acid. The crystals were filtered off and dried (yield: 40 mg (91%)).
Mp: 255-257.0°C.
In a similar way the following compound was synthesized: (3-r2-(3-Nitrobenzoylamino)phenoxylphenyl)phosphonic acid (Compound 145) from {3-[2-(3-nitrobenzoylamino)phenoxy]phenyl}phosphonic acid diethyl ester (110 mg, 0.234 mmol) (yield: 64 mg white crystals (66%)). Mp: 120.4-122.4°C. LC/MS: m/e 415 (M+1).
Example 26
4-(2-Chloro-6-nitrophenoχy)benzenesulfonic acid 2,2-dimethyl-propyl ester
A solution of 4-(2-chloro-6-nitrophenoxy)benzenesulfonyl chloride (0.25 g, 0.72 mmol) and neopentyl alcohol (75 mg, 0.85 mmol) in dry pyridine (0.7 ml) was heated with stirring at 50°C for 20 hours. Subsequent partitioning between methylene chloride and water, followed by isolation and evaporation of the organic phase gave the crude product, which was purified on silica gel (eluent: methylene chloride:methyl tert-butyl ether (10:1 )) to give crystals of 4-(2- chloro-6-nitrophenoxy)-benzenesulfonic acid 2,2-dimethyl-propyl ester (yield: 266 mg (93%)). Mp: 111-112°C. MS: m/e 399 (M+).
Example 27
4-(2-Amino-6-chlorophenoxy)benzenesulfonic acid 2,2-dimethyl-propyl ester 4-(2-chloro-6-nitrophenoxy)-benzenesulfonic acid 2,2-dimethyl-propyl ester (0.25 g,
0.63 mmol) was reduced for 2 days by means of Pt02 (5 mg) at atm pressure in ethanohmethylene chloride (4:1 ) (5 ml). The reaction mixture was filtrated and evaporated to dryness in vacuo to give (2-amino-6-chlorophenoxy)benzenesulfonic acid 2,2-dimethyl-propyl ester, which was used in the next step without purification (yield: 0.12 g (50%)). LC/MS: m/e 370 (M+), 300.
Example 28
4-[2-Chloro-6-(3-nitrobenzoylamino)phenoxylbenzenesulfonic acid 2,2-dimethyl-propyl ester (Compound 146)
(2-Amino-6-chlorophenoxy)benzenesulfonic acid 2,2-dimethyl-propyl ester (43 mg, 0.12 mmol) was dissolved in acetone (10 ml) and triethyl amine (20 μl) and 3-nitrobenzoyl chloride (26 mg, 0.14 mmol) was added. The reaction mixture was stirred at room temperature for 20 hours, filtered and the filtrate evaporated to dryness in vacuo to give 4-[2-chloro-6-(3-nitro- benzoylamino)phenoxy]benzenesulfonic acid 2,2-dimethyl-propyl ester as an oil (yield: 52 mg (86%)). LC/MS: m/e 449 (M - neopentyl).
Example 29
4-r2-Chloro-6-(3-nitrobenzoylamino)phenoxylbenzenesulfonic acid (Compound 147)
A mixture of 4-[2-chloro-6-(3-nitrobenzoylamino)phenoxy]benzenesulfonic acid 2,2- dimethyl-propyl ester (52 mg, 0.10 mmol) and tetraethyl ammonium chloride (54 mg, 0.5 mmol) in DMF (5 ml) was stirred at reflux temperature for 24 hours. The reaction mixture was evaporated and purified on preparative HPLC (Gilson semi-prep.column prep-NOVA- PaK®HRC18, 6 microM, 60 A; Flow: 15 ml/ min Gradient: 5-100% MeCN in water (20 min)) to give 4-[2-chloro-6-(3-nitrobenzoylamino)phenoxy]benzenesulfonic acid (yield: 22 mg (25%)). LC/MS: m/e 449 (M+). Example 30
Dimethyl 4-(2-aminophenoxy)phthalate (0.27 mmol) was dissolved in acetone (1.5 ml). Carboxylic acid chloride (0.27 mmol) and triethyl amine (0.15 ml) were added and the mixture shaken at room temperature for 20 hours. After centrifugation the supernatant was evaporated to dryness in vacuo. The resulting oils were used in the next step without further purification.
4N sodium hydroxide (1 ml) and dioxan (3 ml) were added to the residues and the mixture was shaken at room temperature for 20 hours. The water layer was isolated and evaporated to dryness in vacuo. Water (0.8 ml) was added and pH was adjusted to 2-3 with 6N hydrochloric acid (approx 0.9 ml). The mixture was extracted with ethyl acetate (1.5 ml) and the organic layer was isolated and evaporated to dryness in vacuo.
The following compounds were prepared using the this general parallel fashion methodology:
4-(2-r(2-Chloro-6-methylpyridine-4-carbonyl)aminolphenoxylphthalic acid (Compound 148) from 2-chloro-6-methylpyridine-4-carbonyl chloride and dimethyl 4-(2-aminophenoxy)- phthalate. LC/MS: m/e 427/429 (MH+), 409/411 (MH+-H20).
4-(2-r(2-Chloropyridine-4-carbonyl)aminolphenoxy)phthalic acid (Compound 149) from 2-chloropyridine-4-carbonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 417/414 (MH+), 395/397 (MH+-H20).
4-f2-r(2-p-Tolyloxypyridine-3-carbonyl)aminolphenoxy|phthalic acid (Compound 150) from 2-p-tolyloxypyridine-3-carbonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 485 (M), 467 (M-H20).
4-{2-r(2-Phenoxypyridine-3-carbonyl)aminolphenoxy)phthalic acid (Compound 151 ) from 2-phenoxypyridine-3-carbonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 471 (MH+), 453 (MH+-H20).
4-(2-(r2-(4-Chlorophenoxy)pyridine-3-carbonyllamino|phenoxy)phthalic acid (Compound 152) from 2-(4-chlorophenoxy)pyridine-3-carbonyl chloride and dimethyl 4-(2-aminophenoxy)- phthalate. LC/MS: m/e 505/507 (MH+), 487/489 (MH+-H20).
4-r2-(3,4-Difluorobenzenesulfonylamino)phenoxylphthalic acid (Compound 153) from 3,4-difluorobenzenesulphonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate.
LC/MS: m/e 450 (MH+), 432 (MH+-H20). 4-r2-(4-Chlorobenzenesulfonylamino)phenoxylphthalic acid (Compound 154) from 4-chlorobenzenesulphonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate.
LC/MS: m/e 447/449 (MH+), 430/432 (MH+-H20).
4-f2-(4-Trifluoromethylbenzenesulfonylamino)phenoxylphthalic acid (Compound 155) from 4-trifluoromethylbenzenesulphonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 482 (MH+), 464 (MH+-H20).
4-r2-(4-Nitrobenzenesulfonylamino)phenoxylphthalic acid (Compound 156) from 4-nitromethylbenzenesulphonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate.
LC/MS: m/e 459 (MH+), 441 (MH+-H20). 4-r2-(3-Carboxybenzenesulfonylamino)phenoxylphthalic acid (Compound 157) from 3-chlorosulphonylbenzoic acid and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 458 (MH+), 440 (MH+-H20), 422.
4-r2-(4-Cvanobenzenesulfonylamino)phenoxylphthalic acid (Compound 158) from 4-cyanobenzenesulphonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 439 (MH+), 422 (MH+-H20).
4-(2-r(2,5-Dichlorothiophene-3-carbonyl)amino1phenoxy)phthalic acid (Compound 159) from 2,5-dichlorothiophene-3-carbonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 452/454/456 (MH+), 434/436/438 (MH+-H20).
4-(2-r(5-Bromopyridine-3-carbonyl)aminolphenoxy)phthalic acid (Compound 160) from 3-bromopyridine-3-carbonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 459/457 (MH+), 439/441 (MH+-H20).
4-(2-r(5,6-Dichloropyridine-3-carbonyl)amino1phenoxy)phthalic acid (Compound 161) from 5,6-dichloropyridine-3-carbonyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 447/449/451 (MH+), 429/431/433 (MH+-H20). 4-(2-fr3-Chloro-4-(propane-2-sulfonyl)thiophene-2-carbonyl]aminophenoxy)phthalic acid (Compound 162) from 3-Chloro-4-(isopropylsulphonyl)thiophene-2-carbonyl chloride and dimethyl 4-(2- aminophenoxy)phthalate. LC/MS: m/e 526/524 (MH+), 508/506 (MH+-H20). 4-f2-(4-Chloro-3-nitrobenzoylamino)phenoxy1phthalic acid (Compound 163) from 4-chloro-3-nitrobenzoyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 459/457 (MH+), 441/439 (MH+-H20). 4-r2-(4-Fluoro-3-trifiuoromethylbenzoylamino)phenoxy1phthalic acid (Compound 164) from 4-fluoro-3-trifluoromethylbenzoyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 464 (MH+), 446 (MH+-H20).
4-r2-(4-Methyl-3-nitrobenzoylamino)phenoxylphthalic acid (Compound 165) from 4-methyl-3-nitrobenzoyl chloride and dimethyl 4-(2-aminophenoxy)phthalate. LC/MS: m/e 437 (MH+), 419 (MH+-H20).
Example 31
N-(2-r3,4-Bis-(1 H-tetrazol-5-yl)phenoxylphenyl}acetamide (Compound 166)
A mixture of N-{2-[3-cyano-4-(1 H-tetrazol-5-yl)phenoxy]phenyl}acetamide and N-{2-[4- cyano-3-(1 H-tetrazol-5-yl)phenoxy]phenyl}acetamide (0.45 g, 1.4 mmol) was dissolved in dry DMF (20 ml). Ammonium chloride (0.17 g, 3.1 mmol), sodium azide (0.2 g, 3.1 mmol), and lithium chloride (0.13 g, 3.1 mmol) were added. The reaction mixture was heated at 120°C for 120 hours. The reaction mixture was evaporated in vacuo and purified on a silica gel column (eluent: methylene chloride/methanol (2:1)). The yielded oil was used without any further purification in the next step.
Example 32
N-(2-r3.4-Bis-(1-benzyl-1 H-tetrazol-5-yl)phenoxylphenyl}acetamide (Compound 167)
N-{2-[3,4-Bis-(1 H-tetrazol-5-yl)phenoxy]phenyl}acetamide (0.83 g, 2.3 mmol) was dissolved in dry DMF (20 ml). Potassium carbonate (1.26 g, 9.1 mmol) and benzylbromide (1.26 g, 9.1 mmol) were added and the mixture was stirred for 120 hours at room temperature. The reaction mixture was evaporated in vacuo and purified on preparative HPLC. Eluent acetonitrile/H20 (65:35). N-{2-[3,4-Bis-(1-benzyl-1H-tetrazol-5- yl)phenoxy]phenyl}acetamide was isolated as an oil (yield: 40 mg (3%)). 1H-NMR (CDCI3 in ppm): 2.2 (3H,s); 5.1 (4H, 2xs); 6.9 (1H, d,d); 7.1 (1 H, d,d); 7.15-7.2 (2H, m); 7.25-7.35 (10H,m); 7.55 (1 H,d); 7.65 (1 H.broad s); 7.85 (1 H,d); 8.45 (1 H,d).
Example 33
2-[3,4-Bis-(1 -benzyl-1 H-tetrazol-5-yl)phenoxylphenylamine
N-{2-[3,4-Bis-(1-benzyl-1 H-tetrazol-5-yl)phenoxy]phenyl}acetamide (40 mg, 0.07 mmol) was dissolved in ethanol (10 ml). 4N hydrochloric acid (10 ml) was added and the reaction mixture was refluxed for 15 hours. The mixture was evaporated in vacuo and redissolved in methylene chloride and 0.5 N aqueous sodium hydroxide (1 :1) (20 ml). The organic phase was dried over magnesium sulphate and evaporated in vacuo to give 2-[3,4-bis-(1-benzyl- 1 H-tetrazol-5-yl)phenoxy]phenylamine as an oil (yield: 37 mg (100%)). 1H-NMR (CDCI3 in ppm): 3.9 (2H, broad s); 5.58 (4H, s); 6.75 (1 H, d.d.); 6.85 (1 H,d.d.); 6.9 (1 H,d.d.); 7.0 (1 H,d.d.); 7.1 (1 H,d.d.); 7.2-7.4 (10H,m); 7.48 (1 H,d); 7.8 (1 H,d).
Example 31
N- 2-r3.4-Bis-(1 -benzyl-1 H-tetrazol-5-yl)phenoxylphenyl)-3-nitrobenzamide (Compound 168) 2-[3,4-Bis-(1 -benzyl-1 H-tetrazol-5-yl)phenoxy]phenylamine (37 mg, 0.07 mmol) and
TEA (19 mg, 0.18 mmol) were mixed in acetone (10 ml), and 3-nitrobenzoyl chloride (15 mg, 0.08 mmol) was added. The reaction mixture was stirred for 120 hours at room temperature. The reaction mixture was evaporated in vacuo to an oil. The oil was purified on a silica column with methylene chloride/methanol (39:1) as eluent. The title compound was isolated as yellow oil (yield: 30 mg (62%)).
1H-NMR (CDCI3 in ppm): 5.6 (4H,2xs); 7.0 (1 H,d,d); 7.15 (1 H,d,d); 7.2 (1 H,d,d); 7.25-7.4 (11 H,m); 7.6 (1 H,d,d); 7.73 (1 H,d); 7.9 (1 H,d); 8.1 (1 H,d,d); 8.35 (1 H,d,d); 8.45 (I H.broad s); 8.55 (1 H,d,d); 8.7 (1 H,d,d).
In a similar way the following compounds were prepared: 4-r2-(3,5-Dinitrobenzoylamino)phenoxylphthalic acid dimethyl ester (Compound 169) from 4-(2-aminophenoxy)phthalic acid dimethyl ester, hydrochloride (50 mg, 0.14 mmol) and 3,5-dinitrobenzoyl chloride (35 mg, 0.15 mmol) as a yellow oil (yield: 24 mg (36%)). 1H-NMR (CDCI3) in ppm: δ 3.85 (6H,s); 7.0 (1 H,d.d.); 7.2 (1H,d.d.); 7.25-7.35 (2H,m); 7.72 (2H,d); 8.4 (1 H,d.d.); 8.6 (I H.broad s); 8.95 (2H,d.d.); 9.1 (1 H,d.d.). 4-{2-f2-(2-Nitrophenyl)acetylamino1phenoxy}phthalic acid dimethyl ester (Compound 170) from 4-(2-aminophenoxy)phthalic acid dimethyl ester, hydrochloride (50 mg, 0.25 mmol) and 2-nitrophenylacetyl chloride (91 mg, 0.25 mmol) (yield: 88 mg (76%)). 1H-NMR (CDCI3) in ppm: δ 3.9 (6H,s); 3.95 (2H,s); 6.9 (2H,d.d.); 7.05 (2H,m); 7.15 (I H.d.d.); 7.4 (2H,broad d); 7.55 (I H.d.d.); 7.7 (1H,d); 7.9 (1 H,d); 8.15 (1 H, broad s); 8.4 (1 H,d). 13C-NMR (CDCI3) in ppm: δ 42.4; 53.0; 53.3; 117.0; 118.5; 120,4; 122.1 ; 125.2; 125.4; 126.4; 129.1 ; 129.8; 130.0; 132.0; 133.3; 134.1 ; 135.8; 143.7; 149.0; 159.8; 167.0; 167.7; 168.2.
4-{2-r2-(4-Hvdroxy-3-nitrophenyl)acetylaminolphenoxy)phthalic acid dimethyl ester (Compound 171 ) from 4-(2-aminophenoxy)phthalic acid dimethyl ester, hydrochloride (30 mg, 0.08 mmol) and 3-nitro-4-hydroxyphenylacetyl chloride (17.2 mg, 0.08 mmol) (yield: 30 mg (77%)).
1H-NMR (CDCI3) in ppm: δ 3.65 (2H,s); 3.9 (6H,2xs); 6.8-7.15 (5H,m); 7.25 (1 H,d.d.); 7.4 (1H,d.d.); 7.55 (1H;broad s); 7.75 (1 H,d); 7.95 (1H,d); 8.4 (1 H,d); 10.5 (1 H,broad s). 4-(2-r2-(2-Chloro-5-nitrophenyl)-acetylaminolphenoxy)phthalic acid dimethyl ester (Compound 172) from 4-(2-aminophenoxy)phthalic acid dimethyl ester, hydrochloride (30 mg, 0.08 mmol) and 2-chloro-5-nitrophenylacetyl chloride (19.1 mg, 0.08 mmol) (yield: 37 mg (93%)). H-NMR (CDCI3) in ppm: δ 3.95 (8H,broad d); 6.95 (2H,d.d.); 7.05 (1 H,d); 7.1 (1 H,d.d.); 7.2 (1 H,d.d.); 7.45 (1 H,d)7.48-7.75 (0.5H,m); 7.7 (1 H,d); 7.75 (0.5 H, broad s), 8.0 (I H.d.d.); 8.2 (1H,d); 8.45 (1 H,d.d.).
13C-NMR (CDCI3) in ppm: δ 42.6; 53.0; 53.3; 117.0; 118.5; 120.3; 122.3; 124.2; 125.5; 125.7; 126.8; 130.5; 131.0; 132.1 ; 134.6; 136.0; 141.5; 143.9; 146.9; 159.7; 166.8; 166.9; 168.2.
Example 32
4-{2-r2-(2-Nitrophenyl)acetylaminolphenoxy>phthalic acid (Compound 173)
4-{2-[2-(2-Nitrophenyl)acetylamino]phenoxy}phthalic acid dimethyl ester (88 mg, 0.19 mmol) was dissolved in 2N sodium hydroxide:dioxane (1 :1) (13 ml). The reaction mixture was stirred for 2 hours at room temperature. Then 10N hydrochloric acid was added until pH=1. The reaction mixture was extracted with ethyl acetate (3x30 ml). The ethyl acetate phase was dried with magnesium sulphate, filtered and evaporated in vacuo. To the remaining oil was added acetone and pentane and 4-{2-[2-(2-nitrophenyl)acetylamino]- phenoxyjphthalic acid precipitated as white crystals (yield: 56 mg (71%)). Mp: 208.8-209.2°C. LC-MS: m/e 436 (MH+), 418 (MH+ - H20).
In a similar way the following compounds were synthesized:
4-(2-f2-(4-Hydroxy-3-nitrophenyl)-acetylaminolphenoxy)phthalic acid (Compound 174) from 4-{2-[2-(4-hydroxy-3-nitrophenyl)acetylamino]phenoxy}phthalic acid dimethyl ester as yellow crystals (yield: 27 mg (96%)). Mp: 187.8-189.9°C.
LC-MS: m/e 452 (MH+), 435 (MH+- H20).
4-{2-r2-(2-Chloro-5-nitrophenyl)acetylaminolphenoxy)phthalic acid (Compound 175) from 4-{2-[2-(2-chloro-5-nitrophenyl)acetylamino]phenoxy}phthalic acid dimethyl ester as white crystals (yield: 26 mg (74%)). Mp: 176-178.2°C.
LC-MS: m/e 470 (MH+), 453 (MH+ - H20). Example 33
N-r2-(3,4-Dicyanophenoxy)phenyll-3-nitrobenzamide (Compound 176)
A mixture of 4-(2-aminophenoxy)phthalonitrile (0.5 g, 2.1 mmol), 3-nitrobenzoylchloride (0.43 g, 2.3 mmol) and triethylamine (0.54 g, 0.74 ml, 5.3 mmol) in acetone (20 ml) was stirred for 2 hours at room temperature. The mixture was evaporated in vacuo. The crude product was dissolved in methylene chloride (25 ml) and water (25 ml) and 1 N hydrochloric acid (1 ml) was added. The water phase was extracted with methylene chloride (2x15 ml). The combined organic phase was dried over magnesium sulphate, filtered and evaporated in vacuo giving 700 mg of the crude product. The product was recystallised in acetone/pentane to give white crystals of N-[2-(3,4-dicyanophenoxy)phenyl]-3-nitrobenzamide (yield: 650 mg (81%)). Mp: 176.5-178.1 °C.
PHARMACOLOGICAL METHODS
Rat hepatocytes were isolated using a standard two step collagenase technique, and cultured onto collagen coated culture dishes for 72 hours in medium 199 with the addition of dexamethazone (0.1 mM); penicillin/Streptomycin ((100 u/100 mg)/ml) and insulin (1 nM). During the last 24 hours, the hepatocytes were cultured in the presence of high levels of insulin (5 nM) and glucose (15 mM), which result in the incorporation of glucose into glycogen. Therefore, at the time of the experiment, the cells mimic livers from fed animals. Experiments were initiated after 48 hours of culture by 2 times wash of cells and addition of a 20 mM HEPES experimental buffer including balanced salts, but without glucose. The test compound was added simultaneously with the experimental buffer. To some cultures, glucagon (0.5 nM) was added after 10 minutes in order to stimulate glucose production from liver cells. The glucose released into the media, reflecting the glucose production of the liver cells, was measured 70 minutes after the start of the experiment and standardized to cellular DNA content.
Phosphorylase was either purchased from Sigma or extracted from pig livers according to Stalmans et. al. (Eur.J. Biochem. 49, 415 (1974)), which reference is hereby incorporated by reference. The activity of phosphorylase was determined as described by Bergmeyer (1983; in: Meth. of Enzymatic Analysis 2, 293-295, Weinheim, (ed.) Verlag Chemie), which reference is hereby incorporated by reference.
Compounds of the present invention shows their effect in lowering the glucagon mediated increase in plasma glucose.

Claims

1. A compound of the general formula (I):
Figure imgf000066_0001
as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable basic organic or inorganic addition salt or hydrate or prodrug hereof, wherein
A is -0-, -S-, >SO, >S02, >CO, >CR9R10, or >NR11 ;
R1 and R2 independently are one of the following groups: hydrogen, CN, -C(0)NR6R7, -COOH, -PO(OH)2, -S02OH, tetrazole, 1-hydroxy-1 ,2-diazole, 1-hydroxytriazole, 1- hydroxyimidazole, 2-hydroxytriazole, or 1-hydroxytetrazole; when R1 or R2 is hydrogen, the other of R1 and R2 is -PO(OH)2 or -S02OH; R1 and R2 together may form an anhydride or an imide;
R3 and R4 independently are C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, or C3-8-cycloalkyl, each optionally substituted with halogen, hydroxy, -SH, -SOR6, -S02R6, -NR6R7, -NHCOR7, d-β-alkoxy, N02, trifluoromethoxy, carbamoyl, or -C0NR6R7; or R3 and R4 independently are hydrogen, halogen, perhalomethyl, C1-8-alkoxy, C1-8-alkylthio, -SH, -SOR6, -S02R6, trifluoromethoxy, -S02OH, -PO(OH)2, -COOR6, -CN, hydroxy, -OCOR6, -NR6R7, -NHCOR7, -COCι_β-alkyl, -CONR6R7, -CONHS02R7, -S02NHR7, N02, C1-8-alkoxycarbonyl, aryl, heteroaryl, C1-8-alkylphenyl, or tetrazole; R5 is -CO-R8, -CH2-R8, or -CS-R8; wherein R8 is aryl, C1-8-alkyl, C2-8-alkene, phenyl-
C1-8-alkyl, hetereoaryl, or C3-8-cycloalkyl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S02R6, N02, -NR6R7, -NHCOR7, d-s-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, d.g-alkylth.0, -COOR6, -S02OH, -S02CH3, -PO(OH)2, -CN, -NHCOR7, -CONHS02R7, -S02NHR7, C1-8-alkoxycarbonyl, and tetrazole; wherein
R6 and R7 independently are hydrogen, C1-8-alkyl, aryl, phenyl-C1-8-alkyl, or heteroaryl, each optionally substituted with one or more substituents selected from halogen, OH, NH2, N02, -NH(C1-8-alkyl), -N(C1-8-alkyl)2, -NHCO(C1-8-alkyl), C1-8-alkoxy, and trifluoromethoxy; R9 and R10 independently are hydrogen, hydroxy, -SH, halogen, or C1-8-alkyl; and R11 is hydrogen, C1-8-alkyl, -carbonyl-CLa-alkyl, or phenyl-C1-8-alkyl.
2. A compound according to claim 1 , wherein A is -O- or -S-.
3. A compound according to claim 2, wherein A is -0-.
4. A compound according to any one of the claims 1 to 3, wherein R1 and R2 both are -COOH or CN, preferably -COOH, or R1 and R2 together form an imide.
5. A compound according to any one of the claims 1 to 4, wherein R3 is hydrogen.
6. A compound according to any one of the claims 1 to 5, wherein R4 is hydrogen.
7. A compound according to any one of the claims 1 to 6, wherein R5 is -CO-R8, wherein R8 is as defined in claim 1.
8. A compound according to claim 7, wherein R8 is aryl or hetereoaryl, each optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S02R6, N02, -NR6R7, -NHCOR7, C -8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C1-8-alkylthio, -COOR6, -S02OH, -S02CH3, -PO(OH)2, CN, -NHCOR7, -CONHS02R7, -S02NHR7, C1-8-alkoxycarbonyl, and tetrazole, wherein R6 and R7 are as defined in claim 1.
9. A compound according to claim 8, wherein R8 is aryl optionally substituted with one or more substituents selected from halogen, hydroxy, -SH, -SOR6, -S02R6, N02, -NR6R7,
-NHCOR7, C1-8-alkyl, C1-8-alkoxy, perhalomethoxy, carbamoyl, -CONR6R7, perhalomethyl, -OCOR6, -CO-R6, -OR6, C^-alkylthio, -COOR6, -S02OH, -S02CH3, -PO(OH)2, CN, -NHCOR7, -CONHS02R7, -S02NHR7, C1-8-alkoxycarbonyl, or tetrazole, wherein R6 and R7 are as defined in claim 1.
10. A compound according to claim 9, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents selected from halogen, COOR6, N02, -S02CH3, CN, C1-8-alkyl (preferably methyl, tert-butyl, isopropyl pentyl, heptyl), perhalomethyl (preferably trifluoromethyl),
Figure imgf000067_0001
(preferably methoxy or ethoxy), perhalomethoxy (preferably trifluoromethoxy), C1-8-alkylthio (preferably methylthio), -CO-R6, -NR6R7, -NH- CO-R7, and -OR6, wherein R6 and R7 are as defined in claim 1.
11. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is COOH.
12. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is N02.
13. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) optionally substituted with one or more substituents and at least one of the substituents is halogen
(preferably bromo or chloro).
14. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituent is -CO-R6, wherein R6 is C1-8-alkyl (preferably CH3) or substituted aryl (preferably phenyl) substituted with halogen or substituted with C1-8-alkyl (preferably CH3).
15. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -NH-CO-R7, wherein R7 is C -8-alkyl (preferably CH3).
16. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -NR6R7, wherein R6 and R7 independently are hydrogen or C1-8-alkyl (preferably CH3).
17. A compound according to claim 10, wherein R8 is aryl (preferably phenyl) substituted with one or more substituents and at least one of the substituents is -OCH2R6, wherein R6 is aryl (preferably phenyl).
18. A compound according to claim 8, wherein R8 is benzo[1 ,3]dioxole, 2,3- dihydrobenzofuran, or benzofuran, each optionally substituted with one or more substituents selected from halogen, C1-8-alkyl (preferably methyl), and C1-8-alkoxy (preferably methoxy).
19. A compound according to claim 1 and having the general formula (la):
Figure imgf000068_0001
(la) wherein R1 , R2 and R5 are as defined in claim 1.
20. A compound according to claim 19, wherein R1 and R2 are -COOH.
21. A compound according to claim 20, wherein R5 is -CO-R8 and wherein R8 is as defined in claim 10.
22. A compound according to claim 1 and having the general formula (lb):
Figure imgf000068_0002
wherein R5 is as defined in claim 7.
23. A compound according to claim 22, wherein R5 is -CO-R8 and wherein R8 is as defined in claim 10.
24. A compound according to claim 1 which is 4-[2-(3-dimethylaminobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-dimethylaminobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-iodobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-iodobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2-fluoro-5-trifluoromethylbenzoylamino)phenoxy]phthalic acid , 4-[2-(2-fluoro-5-trifluoromethylbenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2-fluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2-fluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-acetylbenzoylamino)phenoxy]phthalic acid, 4-[2-(3-acetylbenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-bromobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-bromobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-chlorobenzoylamino)phenoxy]phthalic acid,
4-[2-(3-chlorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2,3-difluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2,3-difluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2,4-difluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2,4-difluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(2,5-difluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(2,5-difluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(4-fluorobenzoylamino)phenoxy]phthalic acid, 4-[2-(4-fluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-(2-benzoylaminophenoxy)phthaiic acid,
4-(2-benzoylaminophenoxy)phthalic acid dimethyl ester, 4-[2-(3-methylbenzoylamino)phenoxy]phthalic acid, 4-[2-(3-methylbenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-cyanobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-cyanobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-amino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[4-amino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, N-[2-(1 ,3-dioxo-2,3-dihydro-1 H-isoindol-5-yloxy)phenyl]-3-nitrobenzamide, 4-[2-(3-aminobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-aminobenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[4-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[2-(3-nitrobenzoylamino)phenylsulphenyl]phthalic acid, -[2-(3-nitrobenzoylamino)phenylsulphenyl]phthalic acid dimethyl ester, -[2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, _[4-(4-jodobenzoylamino)-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, _[4-(4-jodobenzoylamino)-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[4-methoxycarbonyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-methoxycarbonyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[4-acetylamino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-acetylamino-2-(3-nitrobenzoyiamino)phenoxy]phthalic acid dimethyl ester, -[5-fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[5-fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[4-bromo-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-bromo-2-(3-nitrobenzoylamino)phenoxy]phthaiic acid dimethyl ester, -[4-benzoylamino-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-benzoylamino-2-(3-nitrobenzoylamino)phenoxy]phthaiic acid dimethyl ester, -[5-methyl-2,4-bis-(3-nitrobenzoylamino)phenoxy]phthaiic acid, -[5-methyl-2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[4-cyano-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-cyano-2-(3-nitrobenzoylamino)phenoxy]phthaiic acid dimethyl ester, -[4,5-dichloro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4,5-dichloro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[5-bromo-4-fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[5-bromo-4-fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[4-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[4-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[4-fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, _[4.fluoro-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[5-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[5-methyl-2-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[2-(3-nitrobenzoylamino)-4-trifluoromethylphenoxy]phthalic acid, -[2-(3-nitrobenzoylamino)-4-trifluoromethylphenoxy]phthalic acid dimethyl ester, -[2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid, -[2,4-bis-(3-nitrobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[2-(3-nitrobenzoylamino)benzyl]phthalic acid, -[2-(3-nitrobenzoylamino)benzyl]phthalic acid dimethyl ester, -[2-(3-fluorobenzoylamino)phenoxy]phthalic acid, -[2-(3-fluorobenzoylamino)phenoxy]phthalic acid dimethyl ester, -[2-(3-trifluoromethylbenzoylamino)phenoxy]phthalic acid, -[2-(3-trifluoromethylbenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-nitrobenzylamino)phenoxy]phthalic acid, 4-[2-(3-nitrobenzylamino)phenoxy]phthalic acid dimethyl ester, 4-[2-(3-trifluoromethoxybenzoylamino)phenoxy]phthalic acid, 4-[2-(3-trifluoromethoxybenzoylamino)phenoxy]phthalic acid dimethyl ester, 4-{benzyl-[2-(3-nitrobenzoylamino)phenyl]amino}phthalic acid,
4-{benzyl-[2-(3-nitrobenzoylamino)phenyl]amino}phthalic acid dimethyl ester, 4-[2-(3-nitrobenzoylamino)phenoxy]phthalic acid, 4-[2-(3-nitrobenzoyiamino)phenoxy]phthaiic acid dimethyl ester, 4-[2-(3-methoxybenzoylamino)phenoxy]phthalic acid, or 4-[2-(3-methoxybenzoylamino)phenoxy]phthalic acid dimethyl ester.
25. A compound according to any one of the claims 1 to 24 for use as a medicament.
26. A pharmaceutical composition comprising, as an active ingredient, a compound according to anyone of the claims 1 to 24 together with one or more pharmaceutically acceptable carriers or diluents.
27. A pharmaceutical composition according to claim 26 in unit form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg and especially preferred from about 0.5 mg to about 200 mg of a compound according to any one of the claims 1 to 23.
28. Use of a compound according to any one of the claims 1 to 24 for the manufacture of a medicament for the treatment or prevention of diabetes, preferably Type 2 diabetes.
29. Use of a compound according to any one of the claims 1 to 24 for the manufacture of a medicament for inhibiting the glucose production from the liver.
30. Use of a compound according to any one of the claims 1 to 24 for the manufacture of a medicament for inhibiting liver glycogen phosphorylase.
31. Use of a compound according to any one of the claims 1 to 24 for the manufacture of a medicament for the treatment or prophylactic of obesity or appetite regulation.
32. A method for the treatment of diabetes, preferably Type 2 diabetes, comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1 to 24 or a pharmaceutical composition according to any one of the claims 26 or 27.
33. A method for the treatment of a glycogen phosphorylase dependent diseases comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1 to 24 or a pharmaceutical composition according to any one of the claims 26 or 27.
34. A method for inhibition of glucose production from the liver comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1 to 24 or a pharmaceutical composition according to any one of the claims 26 or 27.
35. A method for the treatment or prophylaxis of obesity or appetite regulation comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1 to 24 or a pharmaceutical composition according to any one of the claims 26 or 27.
36. A method according to any one of the claims 32 to 35 wherein the effective amount of the compound according to any one of the claims 1 to 24 is in the range of from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg and especially preferred from about 0.5 mg to about 200 mg per day.
37. Any novel features or combination of features as described herein.
PCT/DK2000/000530 1999-09-29 2000-09-28 Novel aromatic compounds WO2001023347A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001526502A JP2003510304A (en) 1999-09-29 2000-09-28 New aromatic compounds
AU74047/00A AU7404700A (en) 1999-09-29 2000-09-28 Novel aromatic compounds
EP00962253A EP1220832A1 (en) 1999-09-29 2000-09-28 Novel aromatic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901384 1999-09-29
DKPA199901384 1999-09-29

Publications (1)

Publication Number Publication Date
WO2001023347A1 true WO2001023347A1 (en) 2001-04-05

Family

ID=8104274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000530 WO2001023347A1 (en) 1999-09-29 2000-09-28 Novel aromatic compounds

Country Status (4)

Country Link
EP (1) EP1220832A1 (en)
JP (1) JP2003510304A (en)
AU (1) AU7404700A (en)
WO (1) WO2001023347A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100819A1 (en) * 2001-06-11 2002-12-19 Dainippon Pharmaceutical Co., Ltd. N-arylphenylacetamide derivatives and medicinal compositions containing the same
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
WO2005020977A1 (en) * 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Alpha-ketoglutarate potentiators of insulin secretion
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7115648B2 (en) 2002-03-06 2006-10-03 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2009030887A2 (en) * 2007-09-04 2009-03-12 Biolipox Ab Bis-aromatic compounds useful in the treatment of inflammation
US7547804B2 (en) 2002-07-15 2009-06-16 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
CN102382076A (en) * 2010-09-03 2012-03-21 中国医学科学院药物研究所 Arone and arylamide compound and preparation method and medicine use thereof
US8772293B2 (en) 2010-07-09 2014-07-08 Pfizer Limited Chemical compounds
US9067922B2 (en) 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds
CN111511717A (en) * 2017-12-20 2020-08-07 日产化学株式会社 Sulfonate compound and use thereof
CN113748103A (en) * 2019-04-26 2021-12-03 日产化学株式会社 Process for producing arylsulfonate compound

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005012221A1 (en) * 2003-08-04 2006-09-14 小野薬品工業株式会社 Diphenyl ether compound, its production method and use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1595520A (en) * 1967-12-13 1970-06-15
GB1427318A (en) * 1972-05-02 1976-03-10 Wiggins Teape Ltd Colour formers
GB1585879A (en) * 1976-08-19 1981-03-11 Centre Nat Etd Spatiales Heterocyclic aromatic polymers of the polymidazopyrrolone class their prepolymers and their preparation
US4298215A (en) * 1979-05-14 1981-11-03 Sterling Drug Inc. Carbonless duplicating and marking systems
DD251550A1 (en) * 1986-07-29 1987-11-18 Wolfen Filmfab Veb METHOD FOR THE CATALYTIC REDUCTION OF AROMATIC NITRO COMPOUNDS
DE4202184A1 (en) * 1992-01-28 1993-07-29 Hoechst Ag Substd. salicylaldehyde derivs. for treating type II diabetes - inhibit glucose-6-phosphatase and gluco-neo genesis in mammals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1595520A (en) * 1967-12-13 1970-06-15
GB1427318A (en) * 1972-05-02 1976-03-10 Wiggins Teape Ltd Colour formers
GB1585879A (en) * 1976-08-19 1981-03-11 Centre Nat Etd Spatiales Heterocyclic aromatic polymers of the polymidazopyrrolone class their prepolymers and their preparation
US4298215A (en) * 1979-05-14 1981-11-03 Sterling Drug Inc. Carbonless duplicating and marking systems
DD251550A1 (en) * 1986-07-29 1987-11-18 Wolfen Filmfab Veb METHOD FOR THE CATALYTIC REDUCTION OF AROMATIC NITRO COMPOUNDS
DE4202184A1 (en) * 1992-01-28 1993-07-29 Hoechst Ag Substd. salicylaldehyde derivs. for treating type II diabetes - inhibit glucose-6-phosphatase and gluco-neo genesis in mammals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XP002901483 *
XP002901484 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084176B2 (en) 2001-06-11 2006-08-01 Dainippon Pharmaceutical Co., Ltd. N-arylphenylacetamide derivatives and medicinal compositions containing the same
WO2002100819A1 (en) * 2001-06-11 2002-12-19 Dainippon Pharmaceutical Co., Ltd. N-arylphenylacetamide derivatives and medicinal compositions containing the same
US7138415B2 (en) 2002-03-06 2006-11-21 Astrazeneca Ab Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
US7332515B2 (en) 2002-03-06 2008-02-19 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7169927B2 (en) 2002-03-06 2007-01-30 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7115648B2 (en) 2002-03-06 2006-10-03 Astrazeneca Ab Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
US7122567B2 (en) 2002-03-06 2006-10-17 Astrazeneca Ab Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
US7129249B2 (en) 2002-03-06 2006-10-31 Astrazeneca Ab Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase
US7166636B2 (en) 2002-03-06 2007-01-23 Astrazeneca Ab Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity
US7547804B2 (en) 2002-07-15 2009-06-16 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
WO2005020977A1 (en) * 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Alpha-ketoglutarate potentiators of insulin secretion
US8507557B2 (en) 2003-08-21 2013-08-13 Wisconsin Alumni Research Foundation Potentiators of insulin secretion
US7863301B2 (en) 2003-08-21 2011-01-04 Wisconsin Alumni Research Foundation Potentiators of insulin secretion
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2009030887A3 (en) * 2007-09-04 2009-06-04 Biolipox Ab Bis-aromatic compounds useful in the treatment of inflammation
WO2009030887A2 (en) * 2007-09-04 2009-03-12 Biolipox Ab Bis-aromatic compounds useful in the treatment of inflammation
US8772293B2 (en) 2010-07-09 2014-07-08 Pfizer Limited Chemical compounds
CN102382076A (en) * 2010-09-03 2012-03-21 中国医学科学院药物研究所 Arone and arylamide compound and preparation method and medicine use thereof
CN102382076B (en) * 2010-09-03 2016-08-17 中国医学科学院药物研究所 Arone and aryl amide compound and preparation method thereof and medicinal usage
US9067922B2 (en) 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds
CN111511717A (en) * 2017-12-20 2020-08-07 日产化学株式会社 Sulfonate compound and use thereof
CN113748103A (en) * 2019-04-26 2021-12-03 日产化学株式会社 Process for producing arylsulfonate compound

Also Published As

Publication number Publication date
JP2003510304A (en) 2003-03-18
AU7404700A (en) 2001-04-30
EP1220832A1 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
WO2001023347A1 (en) Novel aromatic compounds
KR100411323B1 (en) Diaminopropionic acid derivatives
KR101018318B1 (en) Amide derivatives as gk activators
US6590118B1 (en) Aromatic compounds
JP4415216B2 (en) 2-furancarboxylic acid hydrazide compound and pharmaceutical composition containing the same
JP5290065B2 (en) Inhibitors of histone deacetylase
KR101194968B1 (en) 1,1&#39;-1,2-ethynediylbis-benzene derivatives as ptp 1-b inhibitors
US8501982B2 (en) GLP-1 receptor stabilizers and modulators
WO1995030647A1 (en) Cck and gastrin receptor ligands
JP2002544254A (en) Glucagon antagonist / inverse agonist
EP1336607A1 (en) Amide derivatives as glucokinase activators
KR20020013936A (en) Substituted phenoxyacetic acids
EP1654247A1 (en) Alkynyl aryl carboxamides
EP1289936A1 (en) Substituted stilbenes as glucose uptake enhancers
JP2005060385A (en) Medicine comprising 2-furancarboxylic acid hydrazide compound
MXPA01003284A (en) Diaminopropionic acid derivatives
MXPA06005838A (en) Novel salicylic anilides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 526502

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000962253

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000962253

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000962253

Country of ref document: EP